康宁杰瑞
ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY
康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)
Stock code : 9966

2024
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

CONTENTS

About the Report

Reporting Period

The Environmental, Social and Governance ("ESG") Report (the "Report") covers the period from January 1, 2024 to December 31, 2024, with some of the contents extending forward or backward moderately. The period covered herein is consistent with that in our 2024 Annual Report.

Coverage

The entities covered herein are consistent with that in our 2024 Annual Report, including Alphamab Oncology and its subsidiaries.

Reporting Basis

The Report is prepared in accordance with the Environmental, Social and Governance Reporting Code (the "Code") as set out in Appendix C2 of the Rules Governing the Listing of Securities of the Stock Exchange of Hong Kong Limited (the "Stock Exchange") and its major amendments. The Report has been reviewed and approved by the Board of Directors of the Company (the "Board"). Readers may refer to the last chapter of the Report, "Appendix – The Stock Exchange's ESG Reporting Code Content Index" for quick reference.

Sources of Information

The qualitative and quantitative information used in the Report is from public information, internal documents and relevant statistical data of the Company.

Basic Principles

The Report considers the materiality, quantitative, balance and consistency of the key ESG performance indicators.

Materiality

Identify issues that are material to stakeholders through the company growth model of stakeholders.

Quantitative

The disclosed Key Performance Indicators ("KPIs") can be measured.

Balance

Objectively present the Company's work on ESG.

Consistency

Adopt the same data disclosure method as previous years, and compare the data from different years, showing the changes of statistical methods and KPIs.

Pronominal Reference

For ease of presentation and reading, "Alphamab Oncology" is also referred to in the Report as "Alphamab", "the Company" or "We". Unless otherwise defined, capitalized terms and definitions used in the Report shall have the same meaning as defined in the 2024 Annual Report.

Form of Release

The online version of the Report is available for viewing and downloading from the websites of the Stock Exchange (www.hkex.com.hk) and the official website of Alphamab Oncology (www.alphamabonc.com).

About Alphamab Oncology

Founded in 2015, Alphamab Oncology is a biopharmaceutical company dedicated to the development, manufacturing and commercialization of cutting-edge innovative biotherapeutics for cancer treatment. On December 12, 2019, Alphamab Oncology was listed on the Main Board of the Stock Exchange (Stock Code: 9966.HK). Alphamab Oncology has always adhered to the corporate philosophy of "Innovative Medicine for a Better Life", commits to addressing the unmet clinical needs of cancer patients, and strives to develop the next generation of innovative drugs to make cancer controllable and curable.

Our integrated platform seamlessly combines research, development, manufacturing and quality control capabilities for biologics. We take pride in our extensive intellectual property portfolio, which encompasses protein/antibody engineering, antibody screening, and multi-module/multi-functional antibody modification. We have established a differentiated and globally competitive product portfolio, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies. Among them, one product — KN035 (Envafolimab Injection, the world's first subcutaneously injectable programmed cell death-ligand 1 (PD-L1) inhibitor, brand name: ENWEIDA, 恩維達®) — was approved for marketing in China in 2021, providing patients a safer and more convenient cancer immunotherapy. Several other drug candidates are currently in phase III or pivotal clinical trials, and multiple bispecific ADC new drugs are in the preclinical development stage. 2 products were selected as the national "Major New Drug Development and Manufacturing" special project; 3 products were granted 4 Orphan Drug Designations (ODD) by the Food and Drug Administration (FDA) of the U.S.; 2 products received Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA); 1 product was included in the CDE's Pilot Program for Optimizing Clinical Trial Review and Approval of Innovative Drugs.

The following chart outlines our product pipeline as of the date of this Report:

Products	Indications	Combination Therapies	IND	Phase I	Phase II	Pivotal (Phase II/III)	NDA
KN046 (PD-L1/CTLA-4 bispecific antibody)	1L squamous non-small cell lung cancer ("sq NSCLC")	+ chemotherapy					
KN026 (HER2/HER2 bispecific antibody)	≥2L gastric cancer ("GC")/ gastroesophageal junction cancer ("GEJ")	+ chemotherapy					
	1L HER2 positive breast cancer ("BC")	+ nab-docetaxel					
	HER2 positive neoadjuvant BC	+ nab-docetaxel					
KN035 (SubQ PD-L1)	≥2L MSI-H/dMMR advanced solid tumors	monotherapy					
	1L biliary track cancer	+ chemotherapy					
	Neoadjuvant/adjuvant therapy NSCLC	+ chemotherapy					
JSKN003 (HER2 biparatopic ADC)	Late-line HER2-low expression BC	monotherapy					
	Platinum-resistant ovarian cancer ("PROC")	monotherapy					
	≥2L HER2 positive BC	monotherapy					
	HER2-expressing solid tumors	monotherapy					
	1L HER2 positive NSCLC	+ IO/chemotherapy					
JSKN016 (HER3/TROP2 bispecific antibody ADC)	Lung cancer	monotherapy					
	BC	monotherapy					
	Other advanced solid tumors	monotherapy					
	Lung cancer	combination therapy					
	BC	combination therapy					
JSKN033 (subcutaneous co-formulation of JSKN003 and KN035)	Advanced solid tumors	monotherapy					
	Advanced solid tumors	monotherapy					

2024 Highlights

Events of 2024

- KN035 was granted Breakthrough Therapy Designation by the CDE for the treatment of patients with unresectable or metastatic solid tumors with high tumor mutational burden (TMB-H) who have failed prior standard treatment and no satisfactory alternative treatment.
- The results of the phase Ib clinical study of KN046 in combination with chemoradiotherapy as the first-line treatment for recurrent or metastatic esophageal squamous cell carcinoma were published in *Cancer Immunology, Immunotherapy*.

August 2024

- The results of the dose-escalation phase of the phase I clinical trial of JSKN003 conducted in Australia were presented at the American Association for Cancer Research (AACR) annual meeting, which demonstrated favorable tolerability and safety profile of JSKN003 in patients with advanced/metastatic solid tumors who received prior multi-line treatment. The occurrence of hematologic toxicity was very low among common treatment-related adverse events (TRAEs) of all grades and no death or treatment discontinuation was caused by TRAE. The results also demonstrated encouraging preliminary anti-tumor activity.

April 2024

- KN035 (Envafolimab) was registered by the Macau Special Administrative Region ("Macau") Pharmaceutical Administration Bureau for marketing, applicable for the treatment of adult patients with unresectable or metastatic non-microsatellite instability-high (MSI-H)/non-mismatchrepair deficiency (dMMR) advanced solid tumors.
- Alphamab Oncology and 3D Medicines reached an agreement with Glenmark Specialty S.A. (Glenmark), granting Glenmark exclusive rights for the development and commercialization of KN035 for oncology indications in India, the Asia-Pacific region (excluding Singapore, Thailand, and Malaysia), the Middle East and Africa, Russia, the Commonwealth of Independent States (CIS), and Latin America. All development and commercialization costs for KN035 will be solely borne by Glenmark. Alphamab Oncology retains the exclusive rights to manufacture KN035 within and outside the licensed areas for any purpose.

January 2024

- Data from the phase I clinical trial of JSKN003 in China was presented for the first time at the American Society of Clinical Oncology (ASCO) annual meeting. The study showed that JSKN003 achieved an Overall Response Rate (ORR) of 51.1% in patients with HER2-positive and HER2-low expression. Among them, 28 patients previously treated with anti-HER2 therapies reached an ORR of 57.1%, and 21 patients previously treated with anti-HER2 ADCs also reached an ORR of 57.1%, indicating continued efficacy in ADC-pretreated populations.
- Alphamab Oncology signed a research and commercialization collaboration agreement with ArriVent BioPharma,. Inc. (ArriVent) to co-develop novel ADCs using our proprietary linker-payload platform (Alphatecan) and glycan-specific conjugation platform.

June 2024

- The results of the phase II clinical trial of KN046 in combination with chemotherapy as the first-line treatment for metastatic Non-small Cell Lung Cancer (NSCLC) were published in *Cell Reports Medicine*, a sub-journal of *Cell*.
- The first patient has been successfully dosed in Australia in the phase I/II clinical trial of JSKN033 for the treatment of HER2-expressing advanced or metastatic solid tumors, and the dose escalation study has now been concluded.
- JSKN016 was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to conduct a phase I clinical trial for the treatment of advanced malignant solid tumors, with the first patient being dosed in May 2024.
- Envafolimab was included in the 2024 edition of the *Chinese Expert Consensus on the Use of Immune Checkpoint Inhibitors in Perioperative Treatment of Advanced Gastric Cancer* published by the Gastric Cancer Committee of the Chinese Anti-Cancer Association. In 2024, Envafolimab received high recognition from 16 authoritative domestic guidelines and consensuses.

March 2024

- The results of the phase II clinical trial of KN046 in combination with nab-paclitaxel as the first-line treatment for advanced triple-negative breast cancer (BC) were published in *Nature Communications*.

February 2024

September 2024

- The regulatory review for the supplemental application for site, scale, and process changes related to KN035 was completed, and a compliance notification letter was obtained in December 2024.
- Clinical data from two studies on JSKN003 for the treatment of platinum-resistant ovarian cancer (PROC) and advanced HER2-positive (IHC3+) solid tumors (excluding BC) was presented at the European Society for Medical Oncology (ESMO) Congress. The results have demonstrated favorable tolerability and manageable safety profile with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with HER2-expressing breast cancer, PROC, and high HER2-expressing solid tumors.
- The Company reached a licensing agreement with Shanghai JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (CSPC). JMT-Bio was granted the exclusive license and sublicensing rights to develop, sell, and commercialize JSKN003 for the treatment of tumor-related indications in mainland China (excluding Hong Kong, Macau, and Taiwan). In addition, JMT-Bio became the sole marketing authorization holder (MAH[1]) for JSKN003 in mainland China. Alphamab Oncology retains exclusive manufacturing rights for JSKN003. According to the licensing agreement, Alphamab Oncology is entitled to receive upfront and milestone payments of up to RMB 3.08 billion, and a double-digit percentage of royalties based on net product sales of JSKN003.

October 2024

- The phase III clinical trial application for KN026 in combination with albumin-bound docetaxel HB1801 was approved by the CDE as neoadjuvant therapy for HER2-positive early or locally advanced BC and the first patient was successfully dosed in December 2024.

November 2024

- The research results of the first-in-human phase I/II clinical trial of JSKN033 for the treatment of advanced solid tumors were presented in the Late-Breaking Abstract (LBA) session at the 39th annual meeting of the Society for Immunotherapy of Cancer (SITC). According to the study, JSKN033 shows a favorable safety profile and encouraging preliminary anti-tumor activity in heavily pretreated patients with progressing advanced solid tumors.
- The Company was granted "2024 Top 100 Chinese Pharmaceutical Innovative Enterprises" and "2024 China Pharmaceutical Innovative Enterprise Bispecific Antibody Track Top 5" by Healthcare Executive.
- The Company was awarded one of the "2024 Top 100 Brand Influence of Chinese Pharmaceutical Enterprises" by the China Health Culture Association, the Chinese Hospital Association, and the National Health Commission of the People's Republic of China Health TV Channel (CHTV).

December 2024

- Data from the Phase II clinical trial of KN046 in combination with Axitinib as the first-line treatment for advanced NSCLC was presented at the ESMO Immuno-Oncology (IO) Congress 2024.
- JSKN033 received approval from the CDE to initiate a phase I/II clinical trial in Chinese patients with advanced metastatic malignant tumors and the first patient was successfully dosed in January 2025. This study is part of the Pilot Program for Optimizing the Review and Approval of Investigational New Drug (IND) .
- JSKN003 was approved by the CDE to initiate a Phase III clinical trial study to compare the efficacy of JSKN003 with investigator-selected chemotherapy for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, and the first patient was dosed in February 2025.

[1] MAH is short for Marketing Authorization Holder . It refers to an enterprise or institution that has been approved by the drug regulatory authority to hold the marketing authorization for a pharmaceutical product and is responsible for the entire life cycle of the drug, including R&D, manufacturing, marketing, and post-marketing surveillance.

2024 Awards

Throughout the years, we have prioritized scientific and technological innovation as the driving force behind our high-quality development, achieving industry-renowned results. In 2024, we won the following awards:

Going ahead, we at Alphamab Oncology will continue to implement our business strategy of "differentiated innovation driven by clinical needs," and remain committed to our long-term vision of "developing differentiated, clinically valuable and globally competitive new drugs." We will focus on first-in-class drug development, while accelerating clinical research, product launches, and domestic and international collaborations. Through outstanding innovation, we will continue to innovate cancer treatment, bringing hope to patients, and contributing to the development of pharmaceutical industry both home and abroad with more wisdom and strength.

Alphamab Oncology Listed as One of the

"2024 Top 100 Chinese Pharmaceutical Innovative Enterprises"

Jointly launched by Healthcare Executive and Clarivate Analytics, taking the four indications (the number of authorized patents, total number of patent citations, the number of clinical trials and the number of innovative drugs approved and commercialized) as the basis for evaluation, the award selected the "Top 100 Chinese Pharmaceutical Innovative Enterprises" representing China's pharmaceutical innovation strength every year.

Alphamab Oncology has been selected as one of the top 100 for six consecutive years, which ranks among the top pharmaceutical innovators in China, demonstrating its major contribution to the transformation and upgrading of China's pharmaceutical industry and the creation of industrial competitiveness.

Alphamab Oncology Awarded as
"2024 Top 100 Chinese Pharmaceutical Innovative Enterprises" Award

Alphamab Oncology Ranked Among

"2024 China Pharmaceutical Innovative Enterprise Bispecific Antibody Track TOP5"

In November 2024, Alphamab Oncology was awarded the title of the "2024 China Pharmaceutical Innovative Enterprise Bispecific Antibody Track TOP5" by Healthcare Executive. Jointly launched by Healthcare Executive and Clarivate Analytics, the award is based on data screening and a comprehensive evaluation through multiple indicators, including the number of drug candidates in development, clinical pipeline size, authorizing deal value, the number of patents, etc. The awarded companies not only represent the highest level of innovation in cutting-edge fields such as ADCs and bispecific antibodies in China but also have showcased groundbreaking clinical data on the international stage.

Alphamab Oncology Awarded as
"2024 China Pharmaceutical Innovative Enterprise Bispecific Antibody Track TOP5"

Alphamab Oncology Awarded One of the

"2024 Top 100 Brand Influence of Chinese Pharmaceutical Enterprises"

In November 2024, at the "2024 Healthy China Communication Conference" hosted by the China Health Culture Association, the Chinese Hospital Association, and the National Health Commission of the People's Republic of China Health TV Channel (CHTV), the list of "China Pharmaceutical and Healthcare Brand Influence" was officially released. Alphamab Oncology was listed as one of the "2024 Top 100 Brand Influence of Chinese Pharmaceutical Enterprises".

The Brand Influence ranking is determined based on the Brand Influence Index evaluation system developed by the Health Communication Index Research Institute. It collects and analyzes data across multiple dimensions, including pharmaceutical companies' comprehensive capabilities, brand influence, and communication effectiveness. This initiative aims to encourage the entire pharmaceutical industry to place greater emphasis on quality, innovation, and social responsibility, thereby enhancing the sector's overall reputation and credibility. Being named to this prestigious list fully demonstrates Alphamab Oncology's corporate competitiveness, with the R&D efficiency and innovation of its drug and technology platform widely recognized across the industry.



Alphamab Oncology Listed as One of the
"2024 Top 100 Brand Influence of Chinese Pharmaceutical Companies"

01

Sustainable Development Governance

"

Alphamab Oncology remains committed to a robust and sustainable development strategy, underpinned by a comprehensive ESG governance system. Through the establishment of diverse communication channels and a keen attention to the feedback of all shareholders, we strive to enhance the Company's ESG performance across the environmental, social, and governance dimensions. These efforts are aimed at supporting the Company's sustainable development objectives.

ESG Governance Structure

We incorporate the concept of sustainable development into the Company's daily operations and exert continuous efforts to implement ESG management practices. In order to ensure the effective implementation of ESG work, the Company has established and continuously optimized the three-level management structure, which is overall coordinated by the Board, daily supervised by the ESG Working Committee, and implemented by the ESG Working Group, with clearly defined responsibilities at all levels and efficient coordination. The Board, as the supreme responsible body for the ESG governance, guides the Company's ESG development direction.

Decision-making	Board of Directors	• Making decisions on ESG-related risks and importance • Managing and overseeing the handling of ESG issues • Providing guidance, suggestions and support to realize ESG goals
Governance	ESG Working Committee	• Reviewing ESG policies • Supervising and inspecting ESG performance and progress of goal attainment • Identifying and analyzing ESG risks • Reviewing ESG-related reports • Regularly reporting ESG performance to the Board of Directors
Execution	ESG Working Group	• Drafting ESG related policies and actions plans • Coordinating and promoting the handling of various ESG matters • Managing ESG-related risks and matters in routine operation process • Collecting, sorting and preparing public disclosure information on ESG-related matters

Alphamab Oncology ESG Governance Structure

Statement of the Board

Responsibilities of the Board

The Board, as the supreme organization for ESG governance, is responsible for overseeing Alphamab Oncology's ESG strategy development and ESG information disclosure. Specific responsibilities include regularly reviewing and approving ESG strategies and objectives, evaluating ESG-related risks and material issues, reviewing ESG public disclosure information, and dealing with major negative ESG events.

Risk Management

The Board is also responsible for identifying, assessing, and managing ESG-related risks across the Company's operation, ensuring the establishment of appropriate and effective ESG risk management and internal control systems. In addition, under the supervision of the Board, we proactively identify and monitor short-, medium-, and long-term climate-related risks and opportunities, and actively plan to incorporate climate-related risk management into the Company's overall risk management framework.

Materiality Analysis

We attach great importance to the identification of material ESG issues. We evaluate material ESG issues through diversified communication channels, normalized communication mechanisms, and analysis of relevant policies and industry trends. The Company determines material ESG issues mainly according to the materiality evaluation by independent third parties. The final evaluation results are drafted upon discussion and approved by the ESG Working Committee and the Board.

Track of Goals

We set the goals of "reducing energy consumption density, water consumption intensity, and emissions (greenhouse gases, exhaust gases, hazardous and non-hazardous wastes) intensity by 5% as of 2027, with 2024 as the base year". The Board is involved in reviewing and approving ESG strategic goals and continuously monitors on the progress and achievement of these goals. In 2024, Alphamab Oncology achieved reductions in greenhouse gas emission intensity (6.96%), energy consumption intensity (14.40%), and exhaust gas emission intensity (23.22%) compared to 2023—exceeding the set targets.

Communication with Stakeholders

Alphamab Oncology is committed to engaging in interactions with stakeholders. Based on our business characteristics and domestic and international industry practices, we have identified the primary stakeholders who wield decision-making and influence over the Company. Through establishing a standardized communication mechanism, we have adopted diverse engagement strategies such as on-site visits, roadshows, reverse roadshows, strategy conferences and results briefings to listen to, respond to, and meet the demands from all stakeholders. During the reporting period, we conducted over 120 investor communication activities.

Stakeholders	Expectations and Requirements	Company Response	Main Communication Channels
Customers/ potential customers	• Ensure product quality • R&D and innovation • Protect customer privacy and rights	• Quality management • R&D and innovation • Compliance in operation • Responsible publicity • Protection of customers' rights and privacy	• Customer services • Daily operations/communications • Company website • Academic conference • Industry forum
Shareholders and investors	• Protection of shareholders' rights and privacy • R&D and innovation • R&D progress • Commercialization • Information disclosure and transparency • Effective risk control system • Compliance in operation • Intellectual property protection	• Quality management • R&D and innovation • Intellectual property protection • Business cooperation • Compliance in operation • Supply chain management • Emissions management • Resource management	• General Meeting of shareholders • Investor roadshow • Interim and annual results conference • Business progress conference call • Brokerage investment strategy conference or forum • Company website • Results announcements • Interim and annual financial reports • Other information disclosures
Employees	• Employee rights and benefits • Employee training and development • Occupational health and safety	• Employee rights • Employee health and safety • Employee training and development • Compliance in employment • Employee equality and diversity • Employee communication and care	• Team building activities • Employee training • Performance evaluation • Employee suggestion box • Exit interview • Other communications
Suppliers	• Fair procurement • Standardized procurement management	• Supply chain management	• Daily operations • Supplier access and evaluation • Supplier audit
Competitors	• Fair competition • Cooperative development	• Business cooperation • Compliance in operation • Intellectual property protection	• Industry communication • Strategic cooperation • Professional forums
Government and regulators	• Compliance in operation • Corporate governance • Industry development promotion • Community development support • Environmental protection • Energy saving and emission reduction	• Compliance in operation • Emissions management • Resource management • Public and community contribution • Anti-corruption and business ethics	• Regulatory communication • Professional forum • Compliance report • Meetings and visits • Communication with the medical administrators
Communities	• Environmental protection • Public and community contribution	• Public and community contribution • Climate change and response • Emissions management • Resource management • Universal healthcare	• Community activities • Public benefit activities • Seminars • Open Day for Science Popularization • Receive research on employment and science from universities and institutions

Analysis of Material Issues

Alphamab Oncology regularly distributes questionnaires to stakeholders to gather their opinions and expectations regarding the Company's ESG issues. We also prioritize ESG issues with significant impacts on the Company's sustainable development and regularly update our material issues matrix.



The Identification Process of Material Issues at Alphamab Oncology

During the reporting period, we identified 8 highly material issues, 9 moderately material issues, and 3 generally material issues.

Highly material issues	• Quality management • Intellectual property protection • R&D and innovation • Compliance in operation • Business cooperation • Employee rights • Employee health and safety • Responsible publicity
Moderately material issues	• Employee communication and care • Universal healthcare • Supply chain management • Climate change and response • Compliance in employment • Employee training and development • Anti-corruption and business ethics • Resource management • Emissions management
Generally material issues	• Employee equality and diversity • Protection of customers' rights and privacy • Public and community contribution



Matrix of ESG-related Material Issues

02

Steady Development Based on Responsible Management

Alphamab Oncology recognizes compliant operations as the foundation and driving force for our long-term growth and consistently uphold the highest standards of business ethics. Through continuously optimizing our internal management systems and operational mechanisms, we are committed to identify and manage potential risks, laying a solid foundation for achieving sustainable, robust and high-quality development.

- Corporate Governance
- Risk Management
- Business Ethics
- Protection of Intellectual Property Rights

Corporate Governance

The Company adheres rigorously to the *Company Law of the People's Republic of China* and the *Corporate Governance Code* by the Stock Exchange and other applicable laws and regulations. We prioritize enhancing internal governance to safeguard the interests of stakeholders.

We are committed to building an efficient and transparent governance system led by the Board and its committees responsible for the Company's strategic planning and decision-making. In 2024, the Board comprises 6 persons, including 2 executive Directors (one of whom is female), 1 non-executive Director, and 3 independent non-executive Directors. To further regulate the Company's operations, we have established the Audit Committee, the Remuneration Committee, the Nomination Committee, and the Strategy Committee under the Board. These committees fulfill their respective obligations according to their Terms of Reference. During the reporting period, we convened 1 general meeting of shareholders, 4 meetings of the Board of Directors, 2 meetings of the Audit Committee, 1 meeting of the Strategy Committee, and 2 meeting each of the Nomination Committee and the Remuneration Committee. Through cooperation and scientific decision-making, we further enhanced our corporate governance capacity, thereby laying a solid foundation for sustainable development.

Risk Management

Alphamab Oncology continuously improves the internal control system to strengthen our risk prevention, handling and management. The internal control system encompasses various key processes, including the purchasing and payment process, fixed assets process, financial management process, and clinical project management process. We have formulated core documents such as risk lists, risk maps, process narratives, and risk control matrices, and conducted regular audits to ensure the system's effective operation.

In 2024, based on the previous process optimization, we conducted specialized audits focusing on inventory and production management, procurement management, clinical project management and equipment management processes. Meanwhile, we updated and improved the internal control documents of certain processes and identified risk-oriented audits priorities according to the external macro landscape, the Company's development objectives, and operational needs. We have formulated detailed corrective action plans for issues identified during audits, ensuring continuous improvement and implementation of the risk control system. This effort has provided a solid foundation for our sound and robust operations.

Business Ethics

Alphamab Oncology follows the *Anti-Unfair Competition Law of the People's Republic of China*, the *Interim Provisions on Prohibition of Commercial Bribery* and other applicable laws and regulations. Internally, we have formulated a series of anti-corruption rules, including the *Anti-Fraud and Whistleblowing Management Policy*, the *Anti-Bribery and Anti-Corruption Management Policy*, and the *Code of Business Conduct and Ethics*. We firmly adhere to the principles of fairness and justice in our business conduct and have zero tolerance for any form of bribery. In 2024, there were no instances of corrupt practices reported in the Company.

Meanwhile, we enhance employees' clean and self-discipline awareness by conducting anti-fraud training sessions on a regular basis. As of the end of the reporting period, we organized anti-fraud training sessions for all Directors, senior management, and employees. Board directors received a total of 6 hours of training with 6 Directors participating. Additionally, anti-corruption training for employees amounted to 1,260 hours, reaching 420 employees across the organization.

Case **Anti-Fraud Training for All Employees**

In December 2024, Alphamab Oncology conducted anti-fraud training for all employees. The training covered various aspects including internal control, fraud definitions and forms, anti-corruption laws and regulations, and Company-specific requirements. Through case study analysis, employees were able to gain an in-depth understanding of the threats of fraud and the importance of its prevention. At the same time, all members of the Board of Directors received the anti-fraud training materials which cover an overview of fraud and bribery, relevant laws and regulations, and typical cases. This effort aims to comprehensively strengthen their anti-fraud responsibility-fulfilling capacities and raise their compliance awareness.

To fully combat corruption and fraud, we have established various open reporting channels, such as a dedicated hotline and email address to encourage stakeholders to report any misconduct that violates business ethics or laws and regulations. We have also continuously optimized the process of receiving, investigating, and addressing these reports. After verifying the authenticity and accuracy of the reported information, a specialized investigation team will be established to ensure swift and transport responses. In addition, we strictly prohibit the disclosure of whistleblower information and any form of retaliation. In cases where whistleblowers face retaliation for reporting, they have the option to file a complaint with the Internal Control and Audit Department. If retaliation is substantiated following investigation, we hold the responsible parties accountable.

	Unit	2024	2023	2022
Number of concluded corruption lawsuits against the Company or our employees	Case	0	0	0
Number of Directors participating in the training	Person	6	5	6
Number of employees participating in the training	Person	420	435	399
Total anti-corruption training hours provided for Directors	Hour	6	5	6
Total anti-corruption training hours provided for employees	Hour	1,260	1,740	2,793

Protection of Intellectual Property Rights

Prioritizing the protection and management of intellectual property rights ("IPRs"), the Company follows the *Patent Law of the People's Republic of China,* the *Trademark Law of the People's Republic of China*, the *Copyright Law of the People's Republic of China*, and the *Patent Cooperation Treaty (PCT)* and other applicable laws and regulations to build a comprehensive protection system for IPRs. Meanwhile, we strictly prohibit employees from acquiring, disclosing, using, or processing others' IPRs with the acknowledgment of others' innovative contributions. Additionally, we conduct regular checks, searches, and analysis of key patents from competitors or competitive products to prevent any potential infringement. In 2024, the Company was not involved in any lawsuits or disputes related to the infringement of others' IPRs.

To protect our own IPRs, we have secured patents for our innovative pipeline and technology platforms for biomacromolecules, ADCs, and other products in over 20 countries and regions worldwide to safeguard the Company's core technology and product patents. Internally, patent engineers work closely with R&D teams to conduct timely patent searches for new technologies and products, formulate patent application strategies, and coordinate with third-party professional agencies to file patent applications. Upon identifying any potential infringement of the Company's patents or technical secrets, relevant departments will coordinate with third-party agencies to take necessary measures to safeguard our rights and interests.

In addition, Alphamab Oncology comprehensively enhances its IPRs risk management capability by regularly conducting employee training and industry exchanges on IPRs protection.

Employee training

We encourage employees to actively participate in overseas patent layout, technical secret protection, IPRs declaration and other related training to enhance their awareness and capabilities of IPRs protection.

Industry exchanges

We actively participate in the specialized research activities organized by China National Intellectual Property Administration and Suzhou Intellectual Property Bureau to promote exchanges and cooperation between the intellectual property regulators and biopharmaceutical innovation entities.

As of the end of the reporting period, we have filed more than 100 invention patent applications for our key product pipeline and technology platforms, resulting in 45 authorizations to date. In 2024 alone, we submitted 21 invention patent applications and obtained 11 authorized patents.

03

Shared Development Driven by Innovation

Product and technological innovation are integral to the advancement of pharmaceutical companies. We consistently dedicate to biopharmaceutical R&D field, contributing to the patients' health and well-being worldwide on our strong drug R&D capabilities and advanced technology platforms.

- Driving Product Innovation
- Strengthening R&D Strength
- Contributing to Win-win Cooperation
- Protection of the Rights and Interests of the Subjects

Driving Product Innovation

Upholding the philosophy of open collaboration and mutual benefit, we share cutting-edge technologies and innovative results with global industry partners, jointly advancing the R&D and commercialization of anti-tumor drugs.

R&D Innovation System

Alphamab Oncology practice the R&D philosophy of "innovation-driven differentiation and technology-driven safety enhancement". We strictly follow regulatory guidelines, such as ICH Q10 Pharmaceutical Quality System and the *Provisions on On-site Drug Registration Inspections*. The R&D management system is established to cover multiple aspects including R&D document management, data management, laboratory equipment management, and personnel training, effectively standardizing our R&D management and improving efficiency.

At the same time, we are committed to developing differentiated innovative biopharmaceuticals. By optimizing drug design to expand the treatment window, we have made significant breakthroughs in the innovation, safety, and efficacy of anti-tumor drugs based on advantages of our proprietary bispecific antibodies, multifunctional protein engineering, and ADC proprietary technology platforms. We continue to advance core product pipeline differentiated development, providing innovative treatment solutions for patients worldwide.

Looking forward, we will focus on advancing ADCs, especially Bispecific Antibody-Drug Conjugates (BADC) and Bispecific Antibody Dual-Drug Conjugates (BADDC). Based on our innovative platform technologies, such as glycan-specific conjugation, linker-payload, dual payload conjugation, and bispecific antibodies, we aim to continuously overcome technical bottlenecks and promote innovation in the biopharmaceutical industry.

R&D Innovation Results

By promoting the differentiated expansion of our core innovative drug pipeline, we published our latest research findings in several leading international academic journals and world-renowned industry conferences in 2024, further leading the innovation and breakthroughs in the pharmaceutical industry.

Differentiated R&D of Core Innovative Product Pipeline

- Envafolimab, the world's first subcutaneously injectable PD-(L)1 inhibitor, has made a significant breakthrough in the convenience and accessibility of cancer treatment.
- Three phase III clinical studies of KN026, a HER2 bispecific antibody, for the treatment of the second-line GC/GEJ, the first-line HER2-positive BC, and as neoadjuvant therapy of HER2-positive BC were undergoing smoothly and have demonstrated positive progress.
- Three phase III clinical studies of JSKN003, an anti-HER2 biparatopic ADC, for the treatment of HER2-low expressing BC, PROC, and HER2-positive BC as well as multiple exploratory phase II clinical studies are currently undergoing smoothly. JSKN003 was granted breakthrough therapy designation by CDE in March 2025. The designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
- Multiple phase I-II clinical studies in JSKN016, a HER3/TROP2 bispecific ADC, are commenced in succession, for exploring more multi-indication, monotherapy/combination therapies.
- JSKN033, a high concentration co-formulation of ADC and immune checkpoint inhibitor, is the first subcutaneous ADC entering clinical trials. The dose escalation phase has been completed in Australia in the phase I/II clinical study of JSKN033 for the treatment of HER2-expressing advanced or metastatic solid tumors. As a pilot program to optimize the regulatory review and approval process for clinical trials of innovative drugs, its phase I/II research in China were rapidly approved for entering clinical trials.
- Preclinical candidates demonstrate unique structural differentiation and novel pharmacological mechanisms with significant potential.

The latest innovation results of bispecific ADC products were presented on international platforms

- Data from the phase I clinical trials of JSKN003 in Australia and China were presented at AACR, ASCO and ESMO, demonstrating the clinical potential of bispecific ADCs.
- The research results of the first-in-human phase I/II clinical trial of JSKN033 for the treatment of advanced solid tumors, have been presented in the LBA session at the annual meeting of the SITC. JSKN033 presented a favorable safety profile and encouraging anti-cancer activity in heavily treated patients with progressing advanced solid tumors.

Alphamab Oncology's Key R&D Results of Innovative Drugs in 2024

Strengthening R&D Strength

We highly value the R&D platform development. Based on leading technologies of protein engineering, macromolecules process development, and professional formulation, we have successfully established innovation platforms of glycan-specific conjugation, linker-payload, dual-payload conjugation, and bispecific antibodies. We have further enhanced and optimized multiple proprietary drug discovery, research, and manufacturing technology platforms, achieving precise drug delivery, improving drug stability and efficacy, and providing safer and more effective treatment solutions for patients worldwide through technological innovation.

Construction of R&D Platform

In 2024, we made remarkable progress in the R&D innovation of dual-payload conjugation platform, bispecific antibody (CRIB) platform, and new linker-payload platform, further strengthening our core competitiveness in the biopharmaceutical filed.

Dual-payload Conjugation Platform

- Completed the first version selection of the dual toxins (TO1+MMAE)
- Submitted an invention patent application for this platform
- The first project, JSKN021, completed its in vitro and in vivo efficacy evaluations
- Optimized toxin selection, and identified a novel small-molecule compound with a non-cytotoxic mechanism as a potential payload

CRIB Platform

- Incubated a new candidate molecule, JSKN020; antibody molecule was selected, and ADC preparation and optimization was undergoing

Linker-payload Platform

- Refined the platform; the JSKN022 project, incubated from this platform, has completed its pre-toxicology studies with its safety profile identified
- Preliminary data was obtained to support ongoing platform development, with related work continuously progressing

Subcutaneous High-Concentration Formulation Platform

- Enabled the development of highly concentrated drug formulations for subcutaneous injection, featuring long-term storage stability, reduced administration requirements, and improved patient compliance.
- Been successfully applied to ADCs, exemplified by JSKN033—a novel combination of immunotherapy (KN035) and ADC (JSKN003)—demonstrating enhanced efficacy, improved safety, and greater convenience.

Alphamab Oncology's core R&D Platforms Progress in 2024

In addition, we have established an R&D QA[2] team and implemented a series of Standard Operating Procedures (SOPs), systematically optimizing processes for the generation, recording, storage, and management of R&D data. These initiatives aim to standardize R&D operations, reduce the risk of data errors or omissions, and support audit and regulatory inspections. Based on these SOP updates, we have upgraded our Clinical Trial Management System (CTMS), improving system functions, modules, and processes in order to ensure data's consistency and accuracy, while enhancing the clinical research management efficiency. Based on regular system updates by suppliers, we are also able to rapidly respond to customers' feedback and needs, ensuring advanced and adaptive R&D systems while continuously optimizing the clinical research management platform.

[2] QA is short for Quality Assurance, which refers to quality assurance in quality management.

R&D Team Development

Innovative R&D is the core engine driving sustainable corporate growth. We consistently strengthen R&D investment and delve into frontier technologies to maintain our competitive edge in the industry. In 2024, the Company's R&D investment amounted to RMB 404 million.

Cultivating R&D Professionals

We have built a R&D talent team encompassing all R&D stages with a strong focus on cultivating innovative young professionals with high potential. The core members of our team boast extensive experience gained from working in leading international pharmaceutical companies and biologics R&D projects, providing robust technical support for innovation projects. As of the end of the reporting period, the early-stage R&D team composed of the R&D Department, Process Development Department, and Analytical Development Department has reached 55 members, with master's and Ph.D. degree holders constituting 65% of the workforce. The team members' expertise spans multiple specialized fields including protein chemistry, pharmacology, toxicology, and R&D project management, each bringing solid technical expertise and practical experience in drug development.

We put a premium on talent cultivation and technological advancement. Through diversified incentive mechanisms and measures, we aim to inspire innovation within the R&D team and encourage breakthroughs in key technological areas. At the same time, we are committed to building a competitive research environment and career development platform to attract and retain leading R&D professionals, thereby injecting innovation momentum into the Company's long-term growth.

Incorporating Patent Achievements into Performance Management

Incorporate the number of patent applications and authorizations filed by technical staff during their employment into their performance evaluation, with rewards based on results.

Patent achievements from technical staff considered as one of key indicators for local government talent programs.

Talent Recommendation for Local Government Programs

Alphamab Oncology's R&D Talent Incentive Mechanism

On the other hand, to further enhance our R&D team expertise, we conducted specialized training sessions of "ADC preclinical research, model evaluation and transformation", and "protein drugability" in 2024, systematically improving our team's capabilities in innovative drug development. Additionally, we conduct regular on-site inspections of R&D areas and electronic data checks in laboratories, and offer offline training sessions on the *R&D Data Reliability* and the *On-Site Inspections for Drug Registration*, further standardizing the innovation and R&D process.

Additionally, the Company actively encourages R&D professionals to participate in external specialized training and technical exchanges. For instance, in 2024, key R&D personnel were selected to attend the "3rd Global Innovation Summit on Bioconjugate Drugs," enabling in-depth engagement with cutting-edge advancements in ADC drug development.



Specialized Training Session of "ADC Preclinical Research, Model Evaluation and Transformation"

Contributing to Win-win Cooperation

Upholding the core philosophy of open collaboration and mutual benefit, we strive to overcome R&D bottlenecks and promote the efficient and safe new drug's development and commercialization by sharing cutting-edge knowledge and innovative technologies with industry partners. Based on a sound business cooperation system, we have established strategic partnerships with several leading global biopharmaceutical companies, accelerating drug development and market expansion while building a sustainable and coordinated industry ecosystem.

During the reporting period, we made remarkable progress in business operation and established strategic partnerships with multiple leading global biopharmaceutical companies and industry partners, jointly advancing the innovative drugs' R&D and commercialization.

Partners	Cooperation Areas	Cooperation Scope
ArriVent	R&D Cooperation and Clinical and Commercialization Development	Alphamab Oncology reached an agreement with ArriVent to jointly develop new ADC products. Alphamab Oncology retains the rights for development and commercialization of the relevant ADC products in Mainland China, Hong Kong, Macau, and Taiwan, while ArriVent holds exclusive rights for development and commercialization of ADC products in the oncology field in all territories outside the Greater China. ArriVent will also be responsible for and bear the development costs of the ADC products in those territories.
CSPC (JSKN003)	R&D Cooperation and Clinical and Commercialization Development	The Company reached a licensing agreement with JMT-Bio, a wholly-owned subsidiary of CSPC. JMT-Bio was granted the exclusive license and sublicensing rights to develop, sell, and commercialize JSKN003, a HER2 bispecific antibody ADC, for the treatment of tumor-related indications in mainland China (excluding Hong Kong, Macau, and Taiwan). Alphamab retains the sole right to supply JSKN003.
Glenmark (KN035)	Progress in Clinical Development and Commercialization	Alphamab Oncology and 3D Medicines reached a joint agreement with Glenmark, granting Glenmark exclusive rights for the development and commercialization of KN035 for oncology indications in India, the Asia-Pacific region (excluding Singapore, Thailand, and Malaysia), the Middle East and Africa, Russia, the CIS, and Latin America.

Alphamab Oncology's Partners (Non-Exhaustive)

Protection of the Rights and Interests of the Subjects

Alphamab Oncology strictly follows the *Civil Code of the People's Republic of China*, the *Declaration of Helsinki*, the *Good Clinical Practice (GCP)* , the *Guidelines for Ethical Review of Clinical Drug Trials*, and other domestic and international laws and regulations. Internally, we have formulated policies such as the *Protection of the Rights and Interests of Subjects* and the *System Data Entry Guidelines*, effectively regulating the reporting of adverse drug reactions while comprehensively safeguarding subjects' rights and interests.

Meanwhile, we are actively upgrading the Working Instruction (WI) document *Reimbursement Process for Research-Related Medical Expenses and Compensation to Subjects* to enhance compliance in the causality determination of adverse events (AEs) and claims adjudication processes.

During the reporting period, all our clinical studies were successfully reviewed and approved by the Ethics Committee, ensuring that the scientific integrity, reliability, and ethical conduct of clinical trials while fully safeguarding the legal rights and interests of each clinical trial subject. During the implementation of clinical trials, we reinforce the responsibilities and duties of institutions, the Ethics Committee, and sponsors. We implemented protection measures for subjects' rights and interests across multiple aspects, including privacy protection, informed consent, safety assurance, and economic compensation. We also enhance our team's capabilities to enforce these protection and compensation mechanisms through conducting specialized training.

Protection of Subjects' Privacy

The Company has formulated and implemented subjects' privacy protection policies and data security measures, continuously strengthening our data protection process. Meanwhile, internal audits are conducted on the protection of subject's privacy data, ensuring that their personal information is properly safeguarded.

Institutional Guarantee

- We have signed privacy protection agreements with relevant hospitals and researchers, and clarified relevant rights and responsibilities of us and suppliers in contract terms.
- We have established a systematic security event response mechanism for protection of subjects' privacy.

Process Optimization

- We have taken multiple measures to ensure that data is not leaked when formulating clinical trial protocols.

Supervision and Inspection

- Before the implementation of the clinical trial, the Ethics Committee shall evaluate and review the protocols and data confidentiality measures related to the protection of subjects' privacy.

Measures for the Protection of Subjects' Privacy at Alphamab Oncology

Protection of the Subjects' Right to Informed Consent

Before the implementation of any clinical trial, we inform the subjects enrolled in clinical trials with comprehensive information including the study targets, methods, potential conflicts of interest, investigator backgrounds, expected scientific benefits, potential risks, discomforts that may arise, and post-study protection measures. This ensures that the subjects make well-informed decisions based on fully understanding of the research projects.

No procedures are conducted until the subjects have signed the Informed Consent Forms ("ICF"). ICF serves as a cornerstone for safeguarding subjects' rights and interests. The Company develops the ICF according to the clinical study protocol, which is then submitted to the Ethics Committee for approval. If there are any updates to the study information, the ICF is revised accordingly and subjects are informed after approval by the Ethics Committee. If necessary, subjects should sign the updated ICF again.

We respect every subject's right to choose. Subjects have the right to decide whether or not to participate in the study, and they may withdraw at any time without facing adverse effects.

Protection of the Subjects' Right to Safety and Health

Alphamab Oncology has established the *Clinical Trial Safety Report Processing Process* and the *Clinical Study Safety Report Distribution Management Process*, to continually refine the treatment mechanism and process for subjects' adverse events. We ensure that handling is completed within the specified time limits as mandated by regulations in the event of Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Events (SUSARs) during clinical trials. Subsequently, we submit the report to the relevant regulatory authorities, and promptly report to all participating clinical trial investigators, clinical trial institutions and the Ethics Committee, ensuring timely and transparent information dissemination.

Protection of Subjects' Right to Economic Compensation

Alphamab Oncology covers the treatment costs and provides financial compensation for potential trial-related impairment events. We continue to optimize the compensation mechanism and adopt the multi-channel approach combining "insurance claim + third-party supplier compensation + Company compensation" approach. We prioritize the quickest method for settling claims based on the specific circumstances to expedite compensation for subjects, thereby safeguarding their rights and interests to the fullest extent possible.

04

Quality as the Foundation and Adherence to Craftsmanship

"We always put product quality and safety as core mission and continuously improve the quality management system, ensuring compliance throughout the R&D, manufacturing, and clinical trial while safeguarding product quality and patient safety. At the same time, we actively promote workplace safety, customer rights protection, and a sustainable supply chain. We collaborate with customers, suppliers, and other external stakeholders to jointly drive sustainable development across the value chain.

- Ensuring Product Quality
- Adherence to Work Safety
- Refining Service Quality
- Building Responsible Supply Chain

Ensuring Product Quality

We strictly adhere to domestic and international quality-related laws and regulations in alignment with global standards, continuously enhancing our quality management system. Gaps are identified and addressed through internal audits and mock audits conducted by experts both home and abroad. In addition, we conduct employee training sessions to improve the overall quality management.

Quality and Safety Management System

Alphamab Oncology strictly abides by the *Drug Administration Law of the People's Republic of China*, the *Good Manufacturing Practice for Pharmaceutical Products*, the *Good Supply Practice for Pharmaceutical Products*, the *Good Clinical Practice*, the *Administrative Measures for Drug Recalls*, and the *Measures for the Reporting and Monitoring of Adverse Drug Reactions,* and other drug and clinical quality-related laws and regulations. We have systematically updated and optimized management systems in areas of training, MAH, supplier, compliance, validation, site operations, R&D, product release, and clinical operations. This ensures that all processes meet domestic and international regulatory requirements, providing a solid foundation for drug development, manufacturing, and market launch.

To enhance management structure, we have established the Quality Review Board (QRB) as the highest decision-making organization for quality matters. Comprising executives and key personnel from relevant departments, the QRB is tasked with setting the Company's quality guidelines, devising solutions for significant quality events, providing quality evaluation recommendations, and supporting the ongoing enhancement of the quality system. Meanwhile, the QRB holds regular monthly meetings to review and update measures related to quality management and internal audits.

Discussions on quality information, including MAH, clients' demands, laws and regulations updates, and quality management cases	Tracking the progress of quality system review and related actions	Evaluation of KPIs, including quality training, quality variance and changes, Corrective and Preventive Actions (CAPA), product recalls, batch release, batch rejections, complaints, audits, material management, supplier management, and document management

Contents of the QRB Meetings at Alphamab Oncology

Case **PIC/S[3] Quality System Enhancement Project**

In 2024, we launched a comprehensive quality system enhancement project in alignment with PIC/S standards. This project covers regulatory gap analysis, demonstration and review of execution processes and strategies for each module in the system, external third-party gap analysis and mock audits, as well as periodic on-site production inspections. According to PIC/S project requirements, we have continued to promote internal rectifications and system optimizations, comprehensively improving our quality management standards that align with international standards.

At the same time, the quality management targets we set for 2024, including repeat deviation rate, overdue quality event rate, and on-time completion rate of quality training, were all achieved by the end of the reporting period.

[3] PIC/S is short for Pharmaceutical Inspection Co-operation Scheme. PIC/S is an international cooperation organization which consists of drug regulatory authorities from multiple countries. Its goal is to promote global consistency in drug quality and safety by coordinating the Good Manufacturing Practice (GMP) inspection standards.

Clinical Quality Management

In 2024, we revised and added multiple SOPs/WIs covering key areas such as clinical trials, project management, quality control, and data management, further strengthening the quality management system for drug clinical trials. These SOPs/WIs run the entire life cycle of drug production, covering protocol design, organization and implementation, supervision, inspection, recording, analysis, summary and reporting to ensure that the process of clinical trial is standardized and safe, and the data and results are scientific, true and reliable. As of the end of the reporting period, we have a total of 119 internal SOPs/WIs in operation.



Alphamab Oncology's Clinical Management Organization Structure

To improve the product quality inspection process and enhance product quality, we conduct comprehensive internal clinical quality audit on a regular basis each year. These inspections cover various aspects including required documents for clinical trials, regulation or ethics, and informed consent, thereby ensuring strict quality control at every stage of the R&D.

Alphamab Oncology's Quality Inspection Scope

- Required Documents for Clinical Trials
- Regulatory and Ethics Committee
- Responsibilities of Sponsor/Site /CRA
- Informed Consent
- Protocol Deviation
- AE/SAE/SUSAR
- Source Data/Source File Management
- Lab/ Biospecimen Management
- Investigational Product Management
- Electronic Case Report Forms (eCRF)
- Lab Examination/Imaging Tracing
- Facilities and Equipment
- Qualification/Personnel/Training

Strict Product Inspection

We completed 9 comprehensive internal audits of the quality system in strict accordance with internal audit plans during the reporting period. These audits covered all key areas to ensure continuous improvement and effective operation of the quality management system. At the same time, we underwent 3 external audits, including MAH audits and official annual audits for the Envafolimab Injection product. For all minor deficiencies and recommendations during these audits, we promptly implemented corrective measures to smoothly pass the audits.

During the reporting period, we also completed the GMP[4] audits for both the Envafolimab Injection drug substance and manufacturing workshop, and successfully obtained the GMP certificate.

药品 GMP 符合性检查告知书

编号：苏药监药生告知〔2024〕431 号

任务编号	苏 20240010S 新	检查类型	药品 GMP 符合性检查
被检查单位名称	江苏康宁杰瑞生物制药有限公司	药品生产许可证号	苏 20190594
检查地址	依申请检查：苏州工业园区方洲路 175 号		
检查范围及相关车间、生产线	治疗用生物制品[恩沃利单抗注射液，小容量注射剂（非最终灭菌），方洲路厂区原液 1 号车间、制剂 1 号车间，受托生产]		
检查依据	《药品管理法》《药品生产监督管理办法》《药品生产质量管理规范（2010 年修订）》及相关附录		
检查时间	2024 年 09 月 09 日~2024 年 09 月 13 日		
结论	符合要求		
附件	药品 GMP 符合性检查缺陷项目表(已签收)		
主送	江苏康宁杰瑞生物制药有限公司		
抄送	江苏省药品监督管理局苏州检查分局		

重要信息：如不服本告知，可以自收到之日起六十日内向江苏省人民政府申请行政复议，或者在六个月内向江苏省南京市中级人民法院提起行政诉讼。

江苏省药品监督管理局

2024 年 12 月 30 日

Drug GMP Compliance Inspection Notice

Management of Unqualified Products

In terms of unqualified products management, Alphamab Oncology formulated the *Unqualified Products Management Procedures*, clarifying the method for determining unqualified products and the subsequent approval and reporting procedures. In 2024, we introduced a new policy on differentiated scenarios for unqualified products, further improving the handling process. The warehouse, QA engineers (QA) and recipients are explicitly required to jointly confirm the handling records. Through systematic isolation, evaluation and handling unqualified products, we strictly prevent any unqualified products from progressing to subsequent processes or entering the market.



Alphamab Oncology's Unqualified Products Handling Application Process

We have strengthened QA's on-site supervision of the destruction process for unqualified drugs to ensure that handling procedure is compliant and transparent. During the reporting period, the Company did not recall any products for safety or health-related reasons once sold or shipped.

[4] GMP is short for Good Manufacturing Practice. GMP is a set of internationally recognized standards for the production and quality control of pharmaceuticals, designed to ensure that pharmaceuticals are consistently high-quality, safe and effective during the manufacturing process.

Quality Training

To continuously enhance employees' professional qualification and compliance awareness while ensuring the efficient operation of the quality management system, we have strictly implemented our annual GMP training plan. Based on the execution of our internal training system, we have further optimized our training system, including enhancing the training matrix, refining assessment standards, and strengthening requirements for new employee onboarding and hands-on training. This ensured the training content is closely linked with actual work needs. During the reporting period, we successfully conducted 12 quality training sessions and 13 quality forums, reaching an average of 99% of on-time training completion rate.

In addition, each department has established new employee training plans and annual training plans respectively. These training sessions cover a wide range of topics, including industry developments, internal or third-party inspection findings, on-site verification requirements, pharmacovigilance activities, and drug regulatory polices, thereby comprehensively improving employees' professional qualification and compliance awareness.

Pharmacovigilance

Pharmacovigilance is critical for ensuring the drug safety and efficacy. Through establishing a sound pharmacovigilance system, we conduct a thorough risk control of drug safety. We strictly enforce an internal pharmacovigilance audit mechanism, ensuring all related activities comply with applicable laws and regulations as well as SOP requirements. Meanwhile, the Pharmacovigilance team coordinates with the Clinical Quality Assurance Department to regularly inspect suppliers, ensuring that their quality management systems meet the required standards and that drug safety risks are controlled from the source.



Alphamab Oncology's Pharmacovigilance System

Case **Safety Risk Management in R&D Projects**

To improve early-stage R&D projects, we have developed a risk management plan at the initial R&D stage based on preclinical data in combination with information on similar products and literature review. This plan provides risk warnings and control measures for researchers and project team members. As clinical trials progress, we continuously monitor the safety information and dynamically optimize our risk management strategies, ensuring that the safety of subjects is guaranteed.

Pharmacovigilance Awareness Training

Alphamab Oncology places great emphasis on cultivating pharmacovigilance professionals. In 2024, we conducted multiple pharmacovigilance-related training sessions for both new and on-the-job employees from the Pharmacovigilance team. These sessions aimed to enhance employees' professional skills and compliance awareness, ensuring that pharmacovigilance work is carried out efficiently in accordance with regulatory requirements.

New employee training

- Conducted 44 pharmacovigilance SOP/WI training sessions
- Conducted regulation-related training on GCP, Good Pharmacovigilance Practice (GVP) as well as business-related training on pharmacovigilance data systems and public email account management.

On-the-job employee training

- On-the-Job employees participated in "Pharmacovigilance Capacity Enhancement Training Program" organized by Center for ADR Monitoring of Jiangsu. This program covered adverse reactions collection and evaluations, signal detection, and drug instruction revisions.

Alphamab Oncology's Pharmacovigilance Employee Training

Adherence to Work Safety

Alphamab Oncology places utmost importance on work safety management as one of core missions. By improving institutional systems, strengthening on-site management, and implementing laws and regulations, we have built a company-wide work safety management system. Through initiatives such as specialized audits on work safety, unqualified products management, and systematic training, we continuously enhance our work safety capabilities and reinforce our safety defenses.

Work Safety Management System

We place strong emphasis on standardizing work safety management with a focus on "full participation" in safe production. We also continually strengthen the foundation of safety practices, ensuring that safety is integrated into every aspect of our daily operations.

The Company has established a three-tier management system comprising the "Environment, Health and Safety (EHS) Management Committee-Safety Management Organization-Safety Management Personnel", covering all levels of safety production. The EHS Management Committee convenes regular meetings to review and report on EHS-related initiatives and provide guidance to subordinate organizations for daily safety production management. This effort ensures safety production duties are delivered accordingly and that risk management measures are taken effectively.



Alphamab Oncology's Safety Management Structure

On-site Safety

In 2024, we identified and implemented the *Regulations on Safety Risk Management for Production and Operation Units of Jiangsu Province*. By revising the *Work Safety Responsibility System,* we incorporated the latest requirements of laws and regulations into our work safety management system and practiced safety production principles with legal compliance as the bottom line.

Personnel Safety

During the reporting period, we revised several policies, including the *EHS Education and Training Management Policy*, the *Management Systems on Establishing Safety Management Institutions and Safety Management Personnel*, the *Safety Hazard Identification and Governance Management System*, the *Third-Party Safety Management System*, and the *Special Operations Safety Management System*. The revised systems establish a failsafe safety net that extends to all workforce members and associated parties.

Work Safety Operations

In 2024, we conducted specialized safety management audits targeting at inventory, production management, and equipment management, delivering risk control responsibilities while effectively preventing production safety accidents. These efforts ensured that all stages of production and operations aligned with safety compliance requirements. During the reporting period, Alphamab Oncology was recognized as a benchmark enterprise in Suzhou for the "Six Standardizations" of safety management and was awarded the title of *"2024 Suzhou Industrial Park Socially Responsible Enterprise for Safety Production"* by the Suzhou Industrial Park Work Safety Association.

Alphamab Oncology Awarded the Title of *"2024 Suzhou Industrial Park Socially Responsible Enterprise for Safety Production"*

To enhance employees' safety production awareness and operational capabilities, we conduct regular specialized training programs in key production areas. Through a systematic training plan and strict assessment mechanism, employees are enabled to acquire core competencies and follow all relevant regulations, thus reinforcing the foundation of safety production.

Case **Conducted a Specialized Training Session for Aseptic Production to Strengthen Employees' Compliance Awareness**

In 2024, our Formulation Production Department led a specialized training session for aseptic production with a focus on the aseptic production's core aspects and relevant regulatory requirements. The training required participation from multiple departments of Quality, Production, Equipment, Supply Chain, Process Development, and Analytical Development in a hybrid online and offline fashion. All participants were required to pass a post-training assessment, registering a 100% pass rate. This training session has significantly enhanced the employees' expertise and regulatory compliance awareness in aseptic production.

Refining Service Quality

We continuously improve our after-sales service, compliance marketing, and privacy protection system. By establishing a sound customer complaint and product recall management process, strengthening our responsible and compliant marketing management, and conducting training sessions for information security compliance, we aim to create a reliable operational environment to safeguard customer rights and interests.

Customer Complaints Management

At Alphamab Oncology, we regard customer feedback as a critical reference for improving our products and services. To continuously enhance customer satisfaction and ensure product safety, we have been optimizing our customer complaint management system. In 2024, we updated the *Complaint Management Procedures*, further refining complaint handling requirements for clinical-stage products. Additionally, we have established various complaint channels, including email and the official website, to provide customers with transparent and efficient complaint access while ensuring prompt responses and solutions.

Complaint Handling Process of Post-Market Products

To handle customer complaints related to commercial products and clinical trials, we strictly follow established procedures for investigation, classification, and reporting to ensure timely handling and feedback. During the reporting period, we received zero complaint for our commercial products and one quality-related complaint for our clinical products. We conducted a thorough investigation and provided response in strict accordance with our complaint management procedures to ensure timely solution.

Commercial Product Complaint

Quality defect complaints in the CMC (Chemistry, Manufacturing, and Controls) are managed and investigated in strict compliance with the *Complaint Management Procedures*, including complaint classification, thorough investigation, and issuing formal reports. The investigation results are promptly communicated to the MAH

Clinical Complaint

The QA department is responsible for handling complaints. Upon receiving a complaint from customers, clinical trial institutions, or clinical monitors/project managers, the department conducts an investigation and prepares the relevant report accordingly

Alphamab Oncology's Product Complaint Management Mechanism

Product Recall Management

In accordance with the *Administrative Measures for Drug Recalls*, the *Good Manufacturing Practices for Pharmaceutical Products (2010 Edition)*, and the PIC/S and GMP requirements, the Company has revised the *Recall Management Procedures* to add management requirements for overseas product recall. This initiative aims to improve the global post-marketing response mechanism. In 2024, we did not recall any products.

Product Recall Process

Responsible and Compliant Marketing

In strict accordance with laws and regulations such as the *Advertising Law of the People's Republic of China,* the *Drug Administration Law of the People's Republic of China*, the *Management Regulations on Drug Instructions and Labels*, and the *Management Measures for Drug Packaging*, we ensure that all content related to advertising, promotion, drug packaging, and labeling is authentic, accurate, and compliant. Moreover, we prohibit exaggerated promotion or misleading information to safeguarding our reputation and protect the rights and interests of patients.

We have established internal policy documents including the *Management Procedures for Commercial Printed Packaging Materials*, the *Management Procedure for Anti-Counterfeit Packaging of Commercial Products*, and the *Barcode Management Procedure for Commercial Printed Packaging Materials*. These procedures standardize the processes of packaging materials' procurement, design, printing, and use to ensure accurate packaging information, reliable anti-counterfeiting technology, and traceable barcodes, thereby providing strong support for product quality and patient safety.

Protecting Privacy and Security

We place great importance on data security and personal information protection, strictly complying with relevant laws and regulations while continuously strengthening our information security management system. In 2024, we updated the *Information Security Management System*, optimizing security guidelines for employee internet access and management regulations for USB drive. At the same time, we added new controls for phishing email prevention. By continuously improving cybersecurity, virus prevention and control, and data information management measures, we are committed to creating a secure and reliable information environment for users and partners.

In 2024, we optimized our backup structure and cybersecurity defense measures by establishing an electronic document security management system and a network access system. This initiative significantly enhanced our data leak prevention and cybersecurity capabilities, thereby effectively safeguarding core data assets while ensuring business continuity.

Data Security and Cybersecurity Optimizations

- Deploy an electronic document security management system to protect core data assets at the source
- Establish a network access system to restrict access permissions, reducing the risk of spreading threats
- Optimize the backup structure by adding an all-in-one backup machine to enhance data isolation and offline storage
- Upgrade the cybersecurity structure by adding aES software and data center firewalls to reduce attack risks, and reinforce external end protection through a zero-trust gateway

We organize information security training on a regular basis, continuously raising employees' cybersecurity awareness and professional skills while ensuring that every employee master data security operation practices.

Case **The *Information Security Management System* Training**

In February and July 2024, we conducted both online and offline training sessions for information security to further strengthen cybersecurity, virus prevention and control, and data and information management practices based on the *Information Security Management System*. This training supported employees in avoiding common security pitfalls while raising their overall cybersecurity awareness.

Building Responsible Supply Chain

Supply chain management, a critical component of the Company's operations, plays an important role in ensuring product quality, enhancing R&D efficiency, and strengthening market competitiveness. By improving management policies, increasing the intensity of audits and inspections, and promoting responsible procurement practices, we continue to optimize our supplier management system while enhancing supply chain efficiency. At the same time, we conduct supplier training to gradually improve the overall compliance and risk management capabilities in the supply chain, contributing to the high-quality development of the industry.

Supplier Management System

We continue to improve our supplier management system to enhance efficiency while ensuring compliance. In 2024, we updated documents such as the *Material Supplier Management Procedures* and the *Approved Material Supplier List*, optimizing the processes for post-approval materials distribution and supplier change notifications, thereby strengthening the standardization and transparency of supplier management. Additionally, we designed a *Procurement Process Approval* Form to improve the approval processes of procurement and contract while linking the contract approval procedure with the bidding process for easier traceability. During the reporting period, we had a total of 164 new suppliers.

To improve key procurement operations, we have developed management optimization schemes. By expanding communication channels across departments and strengthening cross-functional collaboration, we prioritized critical procurement issues and implemented process tracking management. We also conducted specialized audits of procurement processes, ensuring their efficient operation while supporting the rapid advancement of R&D and clinical projects. To address frequent material arrivals, we have identified materials with lengthy or costly inspections through interviewing and investigation. In collaboration with the planning department, we implemented measures such as procurement orders consolidation and supplier negotiations to improve material inspection efficiency.

As of the end of the reporting period, we had a total of 1,444 suppliers, of which the details of geographical distribution are as follows:

Region	Number of Suppliers
Eastern China	1,040
Southern China	59
Central China	55
Northen China	135
North-western China	25
North-eastern China	10
South-western China	25
Outside China (including Hongkong, Macao, and Taiwan)	95

Supplier Access and Evaluation

We have formulated the *Bidding Management Procedures* and the *Supplier and Supplier Master Data Management Procedures* to standardize the process of supplier selection, evaluation, approval and termination. Furthermore, we have clearly defined the qualifications required for various types of suppliers. Any collaborations with unqualified suppliers will be suspended based on the evaluation results.

In 2024, we strictly abided by the *Material Supplier Management Procedures,* the *Third-party GMP Service Provider Management Procedures*, the *Audit Management Procedures*, and the *2024 Audit Plan* to carry out supplier audits. We completed 37 suppliers' audits in 2024, including 22 periodic audits and 15 project-triggered audits. The audit team, comprising personnel from QA, supplier management along with experts from relevant departments, conducted a hybrid evaluation combining on-site audits with document reviews. This comprehensive assessment covered materials and warehousing, production, releasing, QA/QC[5], and verification to ensure that products, services, and quality management systems provided by our suppliers meet the Company's standards. In 2024, we signed quality agreements with 58 suppliers and completed 16 change assessments and related action items, with no delays or omissions due to personal reasons.

To improve KN035 2000L project, we have completed the files for 35 suppliers and signed quality agreements with 33 suppliers. We also have created a list of qualified suppliers to ensure there are no relevant findings in on-site audits.

For non-GMP suppliers, we conduct annual evaluations targeting the top 10 suppliers by transaction volume in each category. Suppliers failing the evaluation are blacklisted to ensure continuous optimization of our supplier management system.

Supplier Business Ethics Management

Alphamab Oncology adheres to the values of integrity and ethical conduct in supplier process management. During the reporting period, we prompted the majority of our suppliers to sign the *Sunshine Agreement*. We took decisive action against suppliers who breached this agreement, terminating partnerships and blacklisting them accordingly. Alphamab Oncology incorporates environmental and social responsibilities into our supplier evaluation criteria. Suppliers with exemplary environmental and social performance are prioritized based on these criteria.

Domestic Procurement

In 2024, we continuously promoted the utilization of domestically developed materials. We have successfully substitute foreign reagents and consumables with domestically sourced alternatives in departments such as R&D, process development, and QC. For example, detection kits for HCP residues, RNA residues, liquid chromatography N-Glycan, along with various lab consumables, such as sample vials, were domestically sourced on a large scale. During the reporting period, we established partnerships with 15 domestic material suppliers, registering a remarkable achievement in material domestic strategy.

Supplier Communication

We consistently strengthen communication and cooperation with suppliers while expanding cooperation channels. Through systematic training, we also enhance suppliers' quality management capabilities, jointly promoting high-quality and sustainable development of the industry.

In 2024, we conducted targeted supplier training programs based on user needs, covering key topics such as compliance operations and risk management. Additionally, in collaboration with the quality department, we held in-depth discussions with suppliers on issues including materials lead time, quality complaint solutions, and return/replacement procedures. These practices ensured that suppliers have fully understood relevant processes and standards, thereby improving the efficiency and reliability of the supply chain.

[5] QC is short for Quality Control, which refers to the quality control in the quality management.

05

Low-Carbon Development for a Green Future

Low-carbon transition and climate action are considered as key green development paths. We continue to optimize our environmental management system and build a green production operational model aimed at conserving energy and reducing emissions. Moreover, we promote the Company's high-quality development while actively contributing to ecological civilization, thereby injecting new momentum into sustainable growth.

- Strengthening Environmental Regulation
- Practicing Climate Actions
- Enhancing Resource Efficiency
- Emission Compliance Implementation

Strengthening Environmental Regulation

At Alphamab Oncology, we integrate environmental protection into our sustainable development strategy. We strictly adhere to relevant laws and regulations, continuously improve our environmental management system, strengthen environmental risk control, thereby achieving our environmental management targets.

Environmental Management System

In strict accordance with the *Environmental Protection Law of the People's Republic of China*, the *Law of the People's Republic of China on Environmental Impact Assessment*, the *Energy Conservation Law of the People's Republic of China,* and other environmental laws and regulations, Alphamab Oncology has formulated and continuously improved internal protocols such as the *Provisions on Environmental Safety Management of Related Parties* and the *Provisions on Environmental Safety of Chemicals*. In 2024, we revised the *EHS Education and Training Management System*, further enhancing our environmental management and risk control capabilities while reducing the negative environmental impact of our operations.

The Company has established a sound environmental management organizational structure with the EHS Department managing environmental issues and regularly reporting to the executives. The EHS Department complies weekly reports to update executives on the Company's environmental management efforts and coordinates regular training sessions to enhance employees' environment awareness and operational capabilities. These practices aim to continuously promote and implement our environmental management system.

During the reporting period, we conducted clean production training sessions for employees, covering areas such as energy conservation, consumption reduction, and pollution control. These training sessions have effectively enhanced employees' environmental awareness and technical expertise, supporting the Company's efficient resource utilization and improved environmental performance.

Environmental Objectives

We are proactively implementing the national strategic mandate for environmental quality enhancement, collectively forging an ecological conservation shield. We have established energy-saving and emission-reduction objectives based on 2024 emissions (greenhouse gases, exhaust gases, hazardous and non-hazardous wastes), energy use (direct/indirect), and water consumption, along with the ratio of consumption to the original value of utilities and equipment. 2027 is set to be the targeted year of achieving these objectives. By 2027, we strive to reduce the intensity of emissions by 5% annually and reduce energy and water consumption intensity by 5% annually, promoting the Company's sustainable development by taking concrete actions.



2024 Alphamab Oncology Environmental Objectives and Achievement

[6] In 2024, water consumption further increased due to business expansion.

Practicing Climate Actions

Alphamab Oncology ensures environmental management compliance while actively exploring management approaches to address climate change. We have built a governance structure for climate change, systematically identifying climate change-related risks and opportunities while formulating corresponding management strategies and action plans based on the suggestions of the Task Force on Climate-related Financial Disclosures (TCFD). Additionally, we have established multiple climate change-related performance indicators to evaluate the measures' effectiveness and drive ongoing improvements in environmental management through continuous monitoring and quantitative analysis.

Governance

The Company has established an organizational structure to address climate change-related risks. The Board is responsible for developing and reviewing the overall strategic planning and risk objectives. Under the purview of the Board, the ESG Working Committee oversees climate change-related issues, collaborating with various departments to implement actions plans such as greenhouse gas emissions management and energy management. Moreover, the EHS Department holds quarterly meetings to report progress on climate change response and environment protection to the ESG Working Committee, ensuring the continuous improvement and implementation of our climate risk management mechanism.

Strategy

Strictly following the disclosure methods and suggestions of the TCFD, the Company comprehensively evaluates market dynamics, operational aspects, and climate variations in the regions where it operates. Based on this comprehensive analysis, the following climate change-related risks and opportunities have been identified:

Risk Category		Risk Content
Transition Risk	Policy & Legal Risk	Non-compliance with the *Environmental Protection Law of the People's Republic of China* and other relevant laws and regulations could expose the Company to litigation and fines, potentially causing financial losses and damaging its reputation and social credibility.
	Technical Risk	As the Company promotes low-carbon transformation, the ongoing promotion of green technology innovation and R&D may lead to short-term pressure of operating costs.
	Market Risk	Faced with market competition, enterprises demonstrating lower environmental impact are more likely to differentiate themselves, attracting investors and customers—though this may lead to increased environmental protection expenditures.
Physical Risk	Acute Risk	Located in a subtropical monsoon climate zone, the Company faces threats from extreme weather events such as spring droughts, typhoons, floods, and high temperatures. These occurrences have the potential to disrupt or temporarily suspend operations, thereby impacting the Company's revenue.
	Chronic Risk	Climate change-induced abnormal weather patterns, such as extreme heat or cold, may pose a threat to drug stability and storage processes, bringing additional uncertainties into the Company's operations.

To mitigate identified climate change-related risks, we have taken proactive risk response measures. In 2024, we organized "emergency drills on leakage and flooding of dilapidated warehouses", thoroughly testing the feasibility and effectiveness of our emergency response precautionary plans. Meanwhile, in response to Suzhou's prevention and control requirements for heavily polluted weather, we have complied and implemented emergency response measures, effectively reducing pollutant emissions and achieving "peak-cutting" goals. Additionally, boilers are already not allowed to use, thereby further reducing exhaust gas emissions and promoting green and low-carbon operations.

Recognizing the opportunities that rise from climate risks, Alphamab Oncology is transforming these risks into driving forces for growth. We view global climate change as a key opportunity for corporate transformation and upgrading. By identifying and analyzing shifts in market demand, we optimize strategic positioning and seize emerging market opportunities.

Opportunity Category	Opportunity Content
Resource Utilization Efficiency	Through technological innovation, we aim to improve resource utilization efficiency, which is expected to significantly reduce operational costs in the medium to long term.
Energy Strategy	To address potential volatility in traditional energy markets, we plan to integrate renewable energy solutions, ensuring continuous operational stability.
Products and Services	As investors and consumers increasingly favor low-carbon and eco-friendly products, integrating green technologies and innovation into our products and services will enhance the Company's market competitiveness and brand reputation.

Risk and Opportunity Management

We have established a risk prevention and response mechanism comprising pre-incident warning and mitigation, in-process monitoring, and post-incident rectification, further optimizing climate-related risk emergency management. We integrate climate change-related risk management into our overarching risk management framework. During the reporting period, the *Emergency Response Plan for Sudden Environmental Incidents* was successfully filed by the Bureau of Ecology and Environment of the Suzhou Industrial Park. This plan covers specialized sudden environmental events on air pollution, water pollution, and hazardous waste, effectively strengthening our capability to respond to and manage potential climate change-related risks.

Indicators and Targets

We strengthen the monitoring and management system for greenhouse gas emissions to ensure that the emission reduction measures are effectively implemented through real-time emission data tracking.

Indicators	Unit	2024	2023	2022
Total greenhouse gas emissions (Scope 1& Scope 2)[7]	tonne of CO_2 equivalent	13,821.49	12,760.81	11,462.82
Direct greenhouse gas (Scope 1)	tonne of CO_2 equivalent	4,022.89	3,969.51	3,605.45
Indirect greenhouse gas (Scope 2)	tonne of CO_2 equivalent	9,798.60	8,791.30	7,857.37
Greenhouse gas emission intensity per unit of original value of public engineering facilities and machinery equipment	tonne of CO_2 equivalent/ million RMB	46.57	50.05	75.81

[7] Greenhouse gas emissions were calculated in accordance with the Guidelines for Accounting and Reporting of Greenhouse Gas Emissions for Enterprises in Other Industrial Sectors (Trial) issued by the National Development and Reform Commission, the 2006 IPCC Guidelines for National Greenhouse Gas Inventories by the Intergovernmental Panel on Climate Change (IPCC), the General Principles for Calculation of Comprehensive Energy Consumption (GBT 2589-2020), and the 2022 National Grid Emission Factors.

Enhancing Resource Efficiency

Upholding the philosophy of green development, we integrate sustainable growth into our corporate strategy and daily operations. By increasing investment in clean production equipment and technologies, we aim to reduce energy consumption and utilize resources more efficiently, contributing to a green and eco-friendly environment.

Energy Management

Alphamab Oncology places great emphasis on energy management as a critical aspect of sustainable development and continues to advance energy conservation and consumption reduction initiatives. During the reporting period, we replaced our in-house boiler-generated steam with industrial steam from the municipal thermal power plant, effectively reducing energy waste and exhaust gas emissions. Additionally, we conduct regular inspections and maintenance on factory traps by using professional equipment to minimize energy consumption caused by traps' steam leakage.

Case **Realize Green Warehouse Management by Energy-Saving Intervention in Room Temperature Regulation**

In 2024, we ensured optimal storage temperature maintenance through real-time thermal monitoring technology. When the temperature sensor detects that the temperature touches the warning level, the air conditioning reset is carried out automatically. This can ensure that the warehouse environment is stable, and the energy consumption is reduced significantly. After implementation, this project saves about 100,000 kWh of electricity per year and over RMB 80,000 in electricity costs.

In 2024, the Company passed the inspections and audits on two medium/high-cost clean production projects, including replacing gas boilers with municipal steam and upgrading the central air conditioning cooling module. After implementation, these projects are expected to reduce 0.95 tonnes of nitrogen oxides emissions per year and save 380,000 kWh of electricity. While bringing anticipated economic benefits of RMB 1.29 million, these projects make a positive contribution to cities' green and low-carbon development.

Project Name	Description	Benefits	
		Environmental Benefits	Economic Benefits
Replacement of Gas Boilers with Municipal Steam	We purchased municipal steam to replace the existing three 6-tonnes/hour gas boilers to supply steam needed for the Company's operations. This can reduce exhaust gas emissions from burning natural gas. The project was officially implemented in December 2024.	Expected to reduce about 952 kg of organized Amine oxide emissions per year and save about 1.83 million cubic meters of natural gas	Expected to save costs of RMB 980,000 per year
Upgrading of Central Air Conditioning Cooling Module	We purchased lower-power screw chiller units as a backup for the existing three centrifugal chiller units, with a chiller unit switching system. We switch the unit when the temperature is low before and after the winter to reduce the supply of cooling capacity and save electricity. The project was officially implemented in November 2024.	Expected to save about 380,000 kWh of electricity	Expected to save costs of RMB 310,000 per year

Medium/High-Cost Clean Production Projects

During the reporting period, the Company's total energy consumption decreased compare to 2023. The energy consumption intensity per unit of original value of public engineering facilities and machinery equipment decreased by 14.47%.

Indicator	Unit	2024	2023	2022
Electricity	'000kWh	16,659.96	15,415.21	13,777.60
Purchased steam	GJ	386.63	/	/
Gasoline	tonnes	2.34	2.48	3.46
Natural gas	m^3	1,836,561.00	1,811,927.00	1,643,923.00
Direct energy consumption[8]	'000kWh	18,173.96	19,648.35	17,841.02
Indirect energy consumption[9]	'000kWh	16,767.36	15,415.21	13,777.60
Total energy consumption	'000kWh	34,941.31	35,063.56	31,618.62
Energy consumption intensity per unit of original value of public engineering facilities and machinery equipment	'000kWh/million RMB	117.73	137.53	209.11

Water Use Management

We actively practice the water conservation principles of "prioritizing conservation, efficient utilization". We adhere rigorously to the *Water Law of the People's Republic of China*, the *Circular Economy Promotion Law of the People's Republic of China*, and other relevant laws and regulations. Through technological upgrades and process optimization, we promote water conservation in our production. During the reporting period, we designed and implemented multiple no/low-cost clean production water-conservation projects, all of which passed audits and inspections. As a result, we saved 26,485 tonnes of water in 2024, contributing to the sustainable utilization of water. By the end of the reporting period, the Company realized the goal of recycling approximately 71.63 tonnes of regenerated water per day.

Project Name	Description	Benefits	
		Environmental Benefits	Economic Benefits
Water Conservation in Purification Process	The conductivity endpoint for Water-for-Injection (WFI) rinsing in stainless steel distribution systems has been revised from 1μS/cm to 2μS/cm, achieving tap water conservation during pipeline cleaning procedures.	Expected to save **1,000** tonnes of water per year	Expected to save water cost of RMB **4,100** per year
Air Conditioning Humidification Medium Optimization	Through pipeline modification and validation, the humidification medium for air conditioning systems has been changed from pure steam to industrial steam, significantly reducing purified water consumption in pure steam generation processes.	Expected to save **9,645** tonnes of water per year	Expected to save water cost of RMB **39,600** per year

No/Low-Cost Clean Production Water Conservation Projects

[8] Direct energy consumed by the Company consists primarily of oil and natural gas.

[9] The indirect energy consumed by the Company mainly refers to purchased electricity.

During the reporting period, the Company consumed a total of 215,119.85 cubic meters of water with a water consumption density of 724.81 cubic meters per million RMB of original value of public engineering facilities and machinery equipment.

Indicator	Unit	2024	2023	2022
Total water consumption	m^3	215,119.85	179,999.85	191,866.00
Tap water	m^3	188,976.00	169,768.00	182,125.00
Recycled water	m^3	26,143.85	10,231.85	9,741.00
Recycling rate of water resources	%	12.15	5.68	5.08
Water consumption intensity per unit of original value of public engineering facilities and machinery equipment	m^3/million RMB	724.81	706.03	1,268.89

Packaging Material Management

We always stick to the principle of sustainable growth throughout the product lifecycle. By enhancing material recycling, advancing digital management in transportation, and optimizing production processes, we significantly reduce the use of disposable materials, promoting both resource efficiency and environmental protection.

Cold chain transportation of products

- Use recyclable insulated boxes and pre-cooled ice packs
- Adopt digital management for temperature monitoring during the transportation to avoid the use of disposable materials throughout the process

Process technology optimization

- Increase the storage concentration of Envafolimab injection stock solution and reduce the total volume of stock solution to reduce the use of disposable storage bags. By doing so, we reduced the number of storage bags used for Envafolimab from 22 to 6 per batch, effectively reducing the use of storage bags.

Alphamab Oncology Packaging Material Management and Reduction Measures

During the reporting period, the Company consumed a total of 16.65 tonnes of packaging materials and the packaging materials per unit of production was 24.98 g/injection.

Indicators	Unit	2024	2023	2022
Total Packaging Materials	tonnes	16.65	15.22	21.90
Inner Packaging Materials	tonnes	9.23	5.57	12.27
Outer Packaging Materials	tonnes	7.42	9.65	9.63
Packaging materials per unit of production[10]	g/injection	24.98	29.61	57.31

[10] Packaging materials per unit of production = total packaging material consumption / total product output.

Emission Compliance Implementation

The Company highly values green production and strictly adheres to emission management-related laws and regulations, thereby ensuring the compliant disposal of wastewater, exhaust gases, and both hazardous and non-hazardous wastes. Meanwhile, we continue to explore innovative technologies and management methods to reduce pollutant emissions and contribute to a low-carbon and sustainable future.

Wastewater Management

We attach great importance to wastewater management and strictly follow the *Water Pollution Prevention* and *Control Law of the People's Republic of China* and other laws and regulations. We continuously optimize the operation of wastewater treatment facilities and daily management procedures, thereby bolstering treatment effectiveness. We have developed the *Wastewater Treatment and Monitoring Management System*, which clearly requires that the sewage treatment plants conduct regular inspections and monitor wastewater discharge indicators. This ensures that the monitoring data is authentic and effective, and that the wastewater is treated in alignment with standards. Additionally, we actively explore advanced wastewater treatment processes to enhance the effective wastewater management practices.

During the reporting period, the Company discharged a total of 2,003.44 tonnes of wastewater and wastewater discharge intensity per unit of the original value of public engineering facilities and machinery equipment was 6.75 tonnes/ million RMB.

Exhaust Gas Management

Alphamab Oncology strictly follows the *Atmospheric Pollution Prevention and Control Law of the People's Republic of China* and other environmental protection-related laws and regulations. We take comprehensive measures to effectively control emissions of pollutants such as nitrogen oxides (NOx), sulfur oxides (SOx), volatile organic compounds (VOCs), and particulate matter (PM). While ensuring compliance with emission standards, we continuously optimize production and operational equipment and enhance exhaust gas treatment efforts to minimize the environmental impact of our operations.

In 2024, we regularly replaced the activated carbon in our exhaust gas treatment equipment to ensure that the treatment efficiency meet the standard. Based on requirements outlined in our pollutant discharge permit, an exhaust gas monitoring plan was formulated to monitor exhaust gas emissions accordingly, thereby ensuring compliant exhaust gases discharge.

During the reporting period, the total amount of exhaust gas discharged by the Company was 0.39 tonnes and the exhaust gas emission intensity per unit of the original value of public engineering facilities and machinery equipment was 0.001 tonnes/million RMB.

Indicator	Unit	2024	2023	2022
Total exhaust gas emissions	tonnes	0.39	0.44	1.40
Total NOx emissions	tonnes	0.25	0.25	1.18
Total SOx emissions	tonnes	0.00	0.00	0.00
Total PM emissions	tonnes	0.02	0.00	0.07
Total VOCs emissions	tonnes	0.12	0.18	0.12
Total ammonia emissions	tonnes	0.00	0.01	0.03
Exhaust gas emission intensity per unit of the original value of public engineering facilities and machinery equipment	tonnes/million RMB	0.001	0.002	0.01

Waste Management

General Waste

The general solid waste primarily comprises waste paper, waste plastics, food waste, and construction waste produced during our daily operations. Alphamab Oncology adheres to the *Law of the People's Republic of China on the Prevention and Control of Environmental Pollution Caused by Solid Wastes*, along with other relevant laws and regulations. We uphold the principles of "reducing emissions, recycling waste, and pollutant-free treatment", continuously enhancing our internal systems such as the *Solid Waste Management Regulations*. We rigorously oversee the collection, storage, and transfer of solid waste to ensure that all solid waste is handled in a standardized and professional manner.

Hazardous Waste

To dispose of hazardous waste such as membrane package, evaporated residual liquid, waste hazardous chemicals, and wastes contaminated with toxic and hazardous substances, we have established disposal protocols including the *Safety Operation Procedures for Hazardous Waste*. All waste generated is entrusted to qualified third-party organizations for compliant treatment. This ensures that the process of collection, storage, transfer and disposal of waste is compliant, minimizing environmental risks while protecting the ecological system. In 2024, the Company generated 541.53 tonnes of hazardous waste.



Alphamab Oncology's Hazardous Waste Disposal Process

Moreover, we continue to optimize our production processes to reduce hazardous waste emissions while saving cost and supporting green production. During process development, we have successfully reduced the dosage of small-molecule ADC toxins through multiple testing and verification, thereby lowering the emissions of hazardous waste.

During the reporting period, the Company's total waste emissions amounted to 544.53 tonnes and the emission intensity per unit of the original value of public engineering facilities and machinery equipment was 1.84 tonnes/million RMB.

Indicator	Unit		2024	2023	2022
Hazardous waste	tonnes		541.53	270.65	352.32
Non-hazardous waste	tonnes		3.00	3.00	8.00
Total waste discharge	tonnes		544.53	273.65	360.32
Waste discharge intensity per unit of the original value of public engineering facilities and machinery equipment	tonnes/ million RMB	Note: Due to business expansion in 2024, the discharge volume of hazardous waste (e.g. evaporation residues) has increased accordingly.	1.84	1.07	2.38

06

Attracting Talent to Build a Bright Future Together

In today's fiercely competitive labor market, outstanding professionals are integral to the Company's growth. Being steadfast in a people-oriented philosophy, Alphamab Oncology is committed to building a fair, just, and inclusive working environment to ensure every employee can realize their self-worth and growth in the Company.

- Safeguarding Employees' Rights and Interests
- Inspiring Employee Development
- Health and Safety
- Employee Communication and Care

Safeguarding Employees' Rights and Interests

Alphamab Oncology always regards talents as the core driving force for the Company's growth. Through a compliant and impartial recruitment process, the Company protects the employees' legitimate rights and interests while offering competitive remuneration and benefits. This approach attracts top-tier talents, injecting fresh momentum into the Company's development.

Employee Employment

We operate in strict accordance with the *Labor Law of the People's Republic of China*, the *Labor Contract Law of the People's Republic of China,* the *Social Insurance Law of the People's Republic of China*, and other applicable laws and regulations. We have comprehensively upgraded the *Recruitment Management Policy*, the *Labor Contract Management Policy,* the *Employee Code of Conduct and Reward and Punishment System* and other internal management regulations. We strictly prohibit the hiring of child labor and any form of forced labor. Through pre-employment identity verification, we prohibit any form of hiring violation. During the reporting period, there were no incidents of child labor or forced labor within the Company.

Diverse Recruitment

We are dedicated to fostering an environment of equality, inclusivity, and non-discrimination within our workplace. In all aspects of recruitment, onboarding, training, promotion, and rewards, we uphold the principles of "fairness and justice", unequivocally prohibiting any form of employment discrimination based on gender, age, marital or childbearing status, ethnicity, or origin, among other factors. We ensure that all employees enjoy equal employment rights. As of the end of the reporting period, female employees accounted for 55% of the Company's workforce and 35% of senior management are females. This demonstrates our determination and tangible efforts in promoting equal employment and prohibiting gender discrimination.

Talent Assessments

At Alphamab Oncology, we attach great importance on talent attraction and cultivation. We conduct regular talent assessments and inject fresh vigor into the Company through campus and social recruitment endeavors. At the same time, we conduct inbound promotion for key positions and enhance the incentive mechanism for inbound promotion to attract more professionals. In 2024, we have researched and formulated a list of target institutions for school recruitment and established connections with a number of colleges and universities. We also participated in the special job fair for the 2024 graduates of the Medical School of Nanjing University, deeply implementing the joint cultivation and employment promotion program for college students.

Furthermore, we actively participated in several local on-campus recruitment events, successfully hiring two interns and dozens of fresh graduates. These new employees have been assigned to key positions within the Company's R&D, clinical, and commercialization teams, demonstrating our commitment to employee development and capacity building while laying a solid foundation for the Company's long-term sustainable growth.

Talent Team Development

We continue to strengthen efforts in attracting outstanding professionals and are committed to building a high-quality and professional workforce. With rapid business growth in recent years, we have placed greater emphasis on recruiting well-rounded management and technical talents with a global perspective, especially in R&D and clinical fields. We have built a team of talents with high quality, strong ability and the courage to work hard. In 2024, we successfully recruited 36 mid-to-senior-level managers and key technical experts, including 11 professionals at or above associate director level and 24 leading professionals with doctoral or master's degrees. These new recruits not only have strengthened our professional capabilities in R&D, clinical, quality, and manufacturing, but have also injected new vitality into our high-end R&D talent pool, further advancing the Company's innovation capabilities and sustainable development goals.



Number of Employees of Alphamab Oncology by Category in 2024



Employee Turnover Rate of Alphamab Oncology by Category in 2024

Employee Remuneration and Benefits

We strictly comply with domestic and international laws and regulations related remuneration management by improving our internal policies, including the *Remuneration Management Policy*. In 2024, we conducted an overall pay adjustment, further optimizing the compensation structure while ensuring its market competitiveness. At the same time, upholding the principles of "equal pay for equal work and more pay for more work," we provide employees with fair opportunities for salary growth through an open and transparent performance evaluation system.

We always prioritize employee well-being and provide a range of benefits in accordance with applicable laws and regulations. Beyond fulfilling all social insurance obligations based on local regulations, we also offer various benefits such as communication subsidies, high-temperature subsidies, environmental allowances, and regular health checkups. Beyond statutory annual leave, employees are entitled to enjoy additional "welfare leave," and those who work a longer time receive more benefits. Moreover, we distribute various gifts to employees on holidays which can be used personally use or shared as presents with their family and friends. We also provide pre-employment physical examinations, annual physical examinations, and occupational health examinations. First-aid kits are available in all office areas to ensure employees' health and safety.

In 2024, we further incorporated the patent achievements of technical professionals into the performance evaluation system. The number of patent applications or authorizations during their tenure has become a key performance indicator, with corresponding rewards based on assessment results. In addition, we actively support employees in applying for local talent incentives, giving priority to those who have made outstanding contributions in product or technology development, especially those listed as inventors on patent applications.

Moreover, we continue to promote our stock option incentive program. In accordance with relevant policies, stock options were granted to senior management and outstanding employees. During the reporting period, two rounds of stock option incentives were implemented, benefiting a total of 11 employees. This initiative not only provides long-term financial guarantee beyond regular pay but also effectively stimulates employee creativity and engagement, providing a strong support for the Company to retain its core talents.

Other Position-Based Performance Incentives

To motivate employees in different positions and at various career development stages, we have implemented differentiated performance evaluation and incentive programs with timely adjustment and optimization accordingly. A quarterly evaluation model has been established for the clinical CRA team to identify and reward 20% of top-notch performers each quarter. This approach has significantly improved employees' motivation and efficiency, achieving the goal of "more pay for more work with higher quality output". To motivate the clinical coordination team, we launched a more appealing incentive plan to reward high-performing individuals promptly. This practice has not only accelerated clinical trial enrollment but also enhanced employees' sense of belonging and motivation.

Case **"Empowerment, Innovation and Breakthrough" Spring Festival Celebration:Inspiring Employees to Reach New Heights**

In 2024, the Company organized a series of theme events, including the "Empowerment, Innovation. and Breakthrough" Spring Festival Celebration and the "12•12 Innovation Empowerment, Climbing to New Heights" Celebration for the 5th anniversary of our listing. During these events, outstanding employees, exceptional teams, and employees with five years of service in the Company were awarded. These events aim to encourage all employees to strive for excellence in competition and work diligently in each department. As a result, they remain committed to the Company's core values of "innovation, responsibility, integrity, quality, and growth" by sticking to original aspirations and forging ahead with determination.

"Empowerment, Innovation, and Breakthrough" Spring Festival Celebration

Inspiring Employee Development

At Alphamab Oncology, every employee is expected to realize their potential and self-worth. We are committed to striving for the coordinated development of both employees and the Company. Through establishing diversified career development channels, we continuously empower employees to improve their professional skills, building a comprehensive employee growth system.

Employee Promotion

The Company has established a dual-channel promotion path, comprising both technical and management channels. Within this framework, positions at different levels are specified, forming a matrix of talent development paths with departmental positions as the horizontal axis and grades as the vertical axis. This matrix provides employees with more diverse choices for their self-development. In 2024, we made an overall salary adjustment of employees and gave promotion opportunities for employees with excellent performance. In 2024, over 20 employees at Alphamab Oncology were promoted, constituting 5% of the total workforce. Among those promoted, male and female employees each accounted for 50%.

On the other hand, we also actively practice internal job transfer and internal recruitment mechanisms. We comprehensively assess individual performance, job vacancies and employees' personal preferences to make job adjustments. We aim to meet the development needs of employees across different departments.

Employee Training

Alphamab Oncology has built a comprehensive and efficient training system. Through systematic planning and orderly implementation, we regularly hold employee conferences with professional knowledge learning sessions. A comprehensive training management system has been launched, enabling practical applications that enhance employees' professional skills and qualifications. To better integrate training resources, we strive to break down departmental barriers, encouraging sharing and coordinated development of training resources. Targeted courses are jointly designed by each department to share resources from senior lecturers.

At the same time, to improve the efficiency and standardization of training management, we have developed a sound talent training plan based on the operational needs. These courses encompass topics such as human resource (HR), information technology (IT), administration, finance and EHS.

New employee training	• Basic skills training covering human resources (HR), administration, information technology (IT), finance, EHS management, anti-fraud, production, quality and other fields.
Each department's training	• Quality Department: Completed 12 annual training sessions according to the 2024 training plan and held 13 quality forums. • Clinical Quality Department: Organized relevant business departments to interpret 16 updated SOPs, and held 16 open classes, 12 interactive courses, and 1 workshop. • EHS Department: Organized 18 safety training sessions with a total of 2,300 participants, awarding 45 certificates.
Other trainings	• Cooperate with various departments to organize diversified training sessions including the *2024 Anti-corruption Training*, the *Occupational Health and ADC Safety Protection Training* and the *Information Security Management Policy*.

Moreover, to support talents with diverse career development paths, we have also formulated targeted development programs to assist their all-round development.

Case **Management Talent Development**

The Human Resources Department coordinated internal and external resources to conduct multiple specialized training sessions, such as the first management workshop of Alphamab Oncology named "Strong Execution, Closed Loop Management, Mission Accomplished". This workshop aims to strengthen the management's awareness of project management, budget management, and quality management while enhancing their execution power.

Case **Technical Talent Development**

The Quality Assurance Department conducted a training on pollution control strategies, covering relevant regulations and key elements of implementation. Based on the Company's actual production situation, the training was conducted both in-person and online with the participation of the Quality Department, Production Department, Equipment Department, Supply Chain Department, Process Development and Analytical Development Department. To reinforce learning outcomes and ensure practical application, a written assessment was conducted at the end of the session.

In 2024, the Company introduced more than 80 new training courses, such as the *Enrollment Process Methods and Sharing of Common Problems*, the *Interpretation of ICH M10 Regulation (Ligand-Binding Part), A Talk on Project Management*, the *Key Points and Concerns of Clinical Trial On-site Inspections*, the *Crucial Conversation - How to Communicate Effectively*. These courses offer employees knowledge and skill in all aspects from professional knowledge to general office skills, and from management methods to practical work approaches.

The First Management Workshop of Alphmab Oncology

Occupational Health and ADC Drug Safety Protection Training

In 2024, 100% employees of Alphamab Oncology received training sessions. Detailed training information categorized by gender and level are as shown on the right:



Average Training Hours by Gender



Average Training Hours by Level

Health and Safety

Alphamab Oncology always prioritizes the health and safety of employees. In strict accordance with the *Work Safety Law of the People's Republic of China*, the *Law of the People's Republic of China on the Prevention and Control of Occupational Diseases* and other applicable laws and regulations, we have formulated and updated multiple safety regulations, such as the *EHS Education and Training Management Policy*, the *Management Systems on Establishing Safety Management Institutions and Safety Management Personnel*, the *Safety Hazard Identification and Governance Management System*, the *Third-Party Safety Management System*, and the *Special Operations Safety Management System* to ensure to ensure the implementation of our safe production concept. In 2024, we identified and incorporated the latest requirements from the *Regulation on Occupational Diseases Prevention and Control of Jiangsu* and the *Regulation on Safety Risk Management of Production and Operational Entities in Jiangsu*. Furthermore, we have refined the *Occupational Diseases Prevention and Control Management Policy* and the *Work Safety Responsibility System*, integrating new legal requirements into the Company's work safety management system.

We adopt the four major safety management strategies of "focusing on key risks", "clearly defined responsibilities and implementation", "systematic management", and "safety awareness". We establish and enhance a robust safety production responsibility system, set safety targets, identify and address potential hazards and monitor risks.



Alphamab Oncology's Safety Management Strategy

Safety Management Practices

To strengthen safety management practices, the Company has continuously promoted the "one bottom line and three measures" mode to identify safety risks, develop safety training plans, and conduct fire emergency drills. These initiatives have enhanced employees' risk identification capabilities and increased their safety awareness.We also have implemented a reward and punishment system to incentivize employees to report safety risks or contribute to on-site safety management to motivate employees to engage in safety management. Rewards include commendations, performance points, banners, certificates, etc.

One bottom line **Publicity campaigns on relevant laws and regulations**

- Report to the managers of the Company through the weekly EHS work briefings on the Company's operations, including safety production, internal and external accidents, environmental governance, so as to enable the managers to be informed of the Company's daily work and the forms of external safety production and environmental protection;
- Formulate safety training and carry out regular EHS training sessions for employees to raise their awareness.

Three Measures **"Sorting, sequencing, eliminating"**

- Weekly safety inspections and monthly EHS checks are carried out in all departments to sort and categorize safety risks and eliminate them according to priority and ease of rectification.

The Safety Management Mode of "One Bottom Line and Three Measures" of Alphamab Oncology

Safety Hazard Identification

At Alphamab Oncology, we regularly conduct hazardous factors monitoring at workplaces and strictly enforce "Three-Stage" (before, during, and after employment) occupational health check-ups for employees. As of the end of the reporting period, the Company had successfully established comprehensive occupational health records for 119 employees, all of whom passed the "Three-Stage" physical examinations. Workplace hazard monitoring also met the required standards. In addition, a dedicated occupational health and safety training session was conducted to further raise employees' awareness of occupational health and safety.

To ensure effective identification and mitigation of safety hazards, we have established a routine inspection mechanism. Functional departments carry out weekly self-inspections for safety hazards, while the EHS department conducts monthly inspections. Through meticulous on-site inspections, we rigorously verify the compliance with safety regulations and operational procedures. For any delayed or incomplete rectification, the Safety Production Committee issues quarterly notices and sets deadlines for rectification. During the reporting period, all potential safety hazards identified by the Company were rectified.


检测结果报告单

检测编号：XSJZ20241028
受检单位：江苏康宁杰瑞生物制药有限公司
检测类型：定期检测

苏州新世纪检测技术服务有限公司

六、检测结论

七、建议

江苏康宁杰瑞生物制药
有限公司
职业健康检查总结报告书

苏州工业园区疾病防治中心
2024年11月27日

Occupational Health Check-up Report of Alphamab Oncology

Emergency Response Drills

To enhance emergency response capacity building, we process the work in strict accordance with the annual emergency drill and safety training plan. In 2024, we conducted over 10 emergency drills, including emergency drills for poisoning and asphyxiation, on-site disposal of limited space accidents, steam leakage from sterilizers, electric shock accidents, forklift injuries, and sodium hydroxide leakage from CIP stations. 18 safety training sessions under different themes were organized, benefiting 2,300 participants and enabling them to obtain 45 certificates. The safety training covers key areas such as special operations, special equipment, and hazardous chemicals usage, significantly enhancing employees' capabilities to respond to emergencies and their overall professional safety competence.

Safety Emergency Drill

Indicator	Unit	2024	2023	2022
Number of work-related fatalities	Person	0	0	0
Proportion of work-related fatalities	%	0	0	0
Days of work lost due to occupational injuries	Day	0	0	0

Employee Communication and Care

Alphamab Oncology regards feedback from its employees as the driving force for the Company's growth. Through establishing diverse communication channels and regularly organizing employee engagement, employees are enabled to feel valued and supported.

Emails of "kindly reminding employees of expressing their opinions and suggestions"

Suggestion boxes installed in the canteens

President's face-to-face, employee conferences (held from time to time)

Employee Communication Channels at Alphamab Oncology

To enhance information sharing and foster a strong corporate culture, the Company holds regular employee conferences, providing a platform for senior management to discuss industry trends and showcase the Company's latest innovative R&D achievements. Core management provides updates on key project progress and strategic planning while R&D directors share valuable experiences in R&D management. Through these interactions, we aim to foster collaboration among employees, improve work efficiency, and inspire employees to stay innovative and positive in the Company.

The Picture of Employee Conference

Alphamab Oncology cares for the well-being of every employee, dedicating to providing comprehensive care and support. To meet the needs of employees from different age groups, we have designed tailored health check-up programs to ensure the care for employees' health. Additionally, we continuously enhance the facilities of the "Lovely Mommy's Rooms" to create a more comfortable space for female employees who are breastfeeding, thereby increasing employees' happiness and sense of belonging.

In 2024, we thoughtfully organized a range of meaningful activities, such as fitness yoga classes . These activities not only demonstrated care for employees' physical and mental health but also promoted the communication and cooperation among employees, thereby strengthening the Company's cohesion and team spirit.

The Fitness Yoga Class

07

Giving Back to the Community and Building a Better Future

"Guided by the mission of "To make cancer manageable and curable", Alphamab Oncology actively fulfills its corporate social responsibility. Staying true to our original aspiration, we advance universal healthcare and community services through tangible actions, thereby expressing gratitude and giving back to the Society.

Universal Healthcare

Medical Knowledge Empowerment

Universal Healthcare

As a responsible company dedicated to fulfilling its missions, Alphamab Oncology leverages its strengths and capabilities to address the unmet clinical needs of cancer patients worldwide. We continuously develop anti-tumor drugs that are efficient, safe, and globally competitive. Furthermore, we extend our reach to assist more patients in accessing the medications they require for their treatment through patient assistance programs.

Case **The Company's First Commercially Available Drug ENWEIDA (Envafolimab Injection) ——Significantly Reduces the Burden on Healthcare Resources**

ENWEIDA (Envafolimab Injection), the Company's first commercially available drug, is the world's first subcutaneously injectable PD-(L)1 inhibitor approved for cancer immunotherapy. It is also the first immunotherapy drug aimed at cross-tumor indications in China. ENWEIDA can be administered in just 30 seconds, offering unique advantages in effectiveness, safety, convenience, and adherence, which is particularly suitable for frail, elderly patients and those with adverse reactions to intravenous infusions, while significantly reducing the burden on healthcare resources.

Case **Envafolimab Injection Patient Relief Project**

Envafolimab Injection Patient Relief Project was announced in December 2021 and officially launched in January 2022. The Project was updated in December 2023 and is implemented by Simcere, our commercial partner in China. Since its launch, ENWEIDA has benefited over 50,000 patients and has been highly recognized by 16 authoritative guidelines and consensuses recommendations in 2024. The Company donated over 250,000 vials of ENWEIDA.

Medical Knowledge Empowerment

Upholding kindness and fulfilling social responsibilities, Alphamab Oncology insists on continuously spreading warmth and hope. By establishing platforms for popular science education, we take proactive steps to promote innovation and education in medical science and technology, offering the public access to high-quality scientific and technological educational resources. Our objective is to disseminate medical knowledge widely and support the advancement of medical research.

Case **Alphamab Oncology's Science Education Base Contributes to Science, Technology and Innovation Education**

Alphamab Oncology's R&D and Manufacturing Base is recognized as a Science Education Base in Suzhou with a professional team consisting of talents from different areas such as early-stage R&D, clinical development, quality control, and manufacturing. The team is committed to popularizing biomedical knowledge and spreading the idea of scientific medication. In response to the call of the Suzhou Municipal People's Government of promoting science education, we have conducted a wide range of public education activities. In recent years, we have carried out science, technology and innovation education activities under different themes, such as Open Day of Science Popularization and Family Day for primary and secondary school students, university students and citizens from all walks of life.

During open days, primary and secondary school students visited the R&D results exhibition of Alphamab Oncology, where they were shown the whole process of drug development, from R&D to production. By doing so, the students could directly see the importance of researchers' unremitting efforts in developing innovative drugs. In addition, the students also operated professional device under the guidance of the staff to observe the microworld of microbes and explore the wonders behind. This will further spark their interest and enthusiasm in the biopharmaceutical field.



Open Day for Science Popularization

Case **Implementing The Joint Cultivation and Employment Promotion Program for University Students**

Alphamab Oncology places great importance on talent recruitment and development. By formulating a list of target institutions for school recruitment, we have established connections with a number of colleges and universities and participated in the special job fair for university graduates. We also collaborate with universities to implement joint cultivation and employment promotion programs for university students, effectively enhancing the Company's reputation and brand influence.

In 2024, Alphamab Oncology welcomed students from Chemistry and Chemical Engineering School of Southeast University. Participants broadened their scientific and technological horizons through in-depth exploration of laboratories and workshops, further stimulating the interest and enthusiasm of the students in biomedical research. These initiatives not only help the Company build a strong talent pool but also contribute to talent cultivation and technological innovation in the industry.


Visits by Students from Southeast University

Appendix

The Stock Exchange's ESG Reporting Code Content Index

Environmental, Social and Governance Subject Areas, General Disclosures and KPIs			Chapter in this Report
A. Environment			
A1: Emissions	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	Low-Carbon Development for a Green Future
	A1.1	The types of emissions and respective emissions data.	ESG Key Performance Indicators
	A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g., per unit of production volume, per facility).	ESG Key Performance Indicators
	A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	ESG Key Performance Indicators
	A1.5	Description of emission target(s) set and steps taken to achieve them.	Low-Carbon Development for a Green Future
	A1.6	Description of how hazardous and non- hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	Low-Carbon Development for a Green Future
A2: Use of Resources	General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	Low-Carbon Development for a Green Future
	A2.1	Direct and/ or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	ESG Key Performance Indicators
	A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	ESG Key Performance Indicators
	A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	Low-Carbon Development for a Green Future
	A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	Low-Carbon Development for a Green Future
	A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	ESG Key Performance Indicators
A3: The Environment and Natural Resources	General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	Low-Carbon Development for a Green Future
	A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	Low-Carbon Development for a Green Future
B. Social			
Employment and Labour Practices			
B1: Employment	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	Attracting Talent to Build a Bright Future Together
	B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	ESG Key Performance Indicators
	B1.2	Employee turnover rate by gender, age group and geographical region.	ESG Key Performance Indicators
B2: Health and Safety	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	Attracting Talent to Build a Bright Future Together
	B2.1	Number and rate of work-related fatalities occurred in each of the past three years, including the reporting year.	ESG Key Performance Indicators
	B2.2	Lost days due to work injury.	ESG Key Performance Indicators
	B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	Attracting Talent to Build a Bright Future Together
B3: Development and Training	General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Attracting Talent to Build a Bright Future Together
	B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	ESG Key Performance Indicators
	B3.2	The average training hours completed per employee by gender and employee category.	ESG Key Performance Indicators
B4: Labour Standards	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	Attracting Talent to Build a Bright Future Together
	B4.1	Description of measures to review employment practices to avoid child and forced labour.	Attracting Talent to Build a Bright Future Together
	B4.2	Description of steps taken to eliminate such practices when discovered.	Attracting Talent to Build a Bright Future Together
Operating Practices			
B5: Supply Chain Management	General Disclosure	Policies on managing environmental and social risks of the supply chain.	Quality as the Foundation and Adherence to Craftsmanship
	B5.1	Number of suppliers by geographical region.	ESG Key Performance Indicators
	B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	Quality as the Foundation and Adherence to Craftsmanship
	B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	Quality as the Foundation and Adherence to Craftsmanship
	B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	Quality as the Foundation and Adherence to Craftsmanship
B6: Product Responsibility	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	Quality as the Foundation and Adherence to Craftsmanship
	B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Quality as the Foundation and Adherence to Craftsmanship
	B6.2	Number of products and service related complaints received and how they are dealt with.	Quality as the Foundation and Adherence to Craftsmanship
	B6.3	Description of practices relating to observing and protecting intellectual property rights.	Quality as the Foundation and Adherence to Craftsmanship
	B6.4	Description of quality assurance process and recall procedures.	Quality as the Foundation and Adherence to Craftsmanship
	B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	Quality as the Foundation and Adherence to Craftsmanship
B7: Anti-corruption	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	Steady Development Based on Responsible Management
	B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	Steady Development Based on Responsible Management
	B7.2	Description of preventive measures and whistle-blowing procedures, how they are implemented and monitored.	Steady Development Based on Responsible Management
	B7.3	Description of anti-corruption training provided to directors and staff.	Steady Development Based on Responsible Management
Community			
B8: Community Investment	General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	Giving Back to the Community and Building a Better Future
	B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	Giving Back to the Community and Building a Better Future
	B8.2	Resources contributed (e.g. money or time) to the focus area.	Giving Back to the Community and Building a Better Future

ESG Key Performance Indicators

Environment	2022	2023	2024
Emission			
Total greenhouse gas emissions (Scope 1 & Scope 2) (tonne of CO_2 equivalent)	11,462.82	12,760.80	13,821.49
Direct greenhouse gas (Scope 1)	3,605.45	3,969.51	4,022.89
Indirect greenhouse gas (Scope 2)	7,857.37	8,791.30	9,798.60
Direct greenhouse gas emission intensity per unit of original value of public engineering facilities and machinery equipment (Scope 1) (tonne of CO_2 equivalent/million RMB)	23.84	15.57	13.55
Indirect greenhouse gas emission intensity per unit of original value of public engineering facilities and machinery equipment (Scope 2) (tonne of CO_2 equivalent/million RMB)	51.96	34.48	33.01
Greenhouse gas emission intensity per unit of original value of public engineering facilities and machinery equipment (tonne of CO_2 equivalent/million RMB)	75.81	50.05	46.57
Total exhaust gas emissions (tonnes)	1.40	0.44	0.39
Total NO_x emissions	1.18	0.25	0.25
Total SO_x emissions	0.00	0.00	0.00
Total PM emissions	0.07	0.00	0.02
Total VOCs emissions	0.12	0.18	0.12
Total ammonia emissions	0.03	0.01	0.00
Exhaust gas emission intensity per unit of the original value of public engineering facilities and machinery equipment (tonnes/million RMB)	0.01	0.002	0.001
Total waste discharge (tonnes)	360.32	273.65	544.53
Hazardous waste	352.32	270.65	541.53
Non-hazardous waste	8.00	3.00	3.00
Hazardous waste discharge intensity per unit of the original value of public engineering facilities and machinery equipment (tonnes/million RMB)	2.33	1.06	1.83
Non-hazardous waste discharge intensity per unit of the original value of public engineering facilities and machinery equipment (tonnes/million RMB)	0.05	0.01	0.01
Waste discharge intensity per unit of the original value of public engineering facilities and machinery equipment (tonnes/million RMB)	2.38	1.07	1.84
Resource consumption			
Total water consumption (m^3)	191,866.00	179,999.85	215,119.85
Tap water	182,125.00	169,768.00	188,976.00
Recycled water	9,741.00	10,231.85	26,143.85
Recycling rate of water resources (%)	5.08	5.68	12.15
Water consumption intensity per unit of original value of public engineering facilities and machinery equipment (m^3/million RMB)	1,268.89	706.03	724.81
Electricity ('000kWh)	13,777.60	15,415.21	16,659.96
Purchased steam (GJ)	/	/	386.63
Natural gas (m^3)	1,643,923.00	1,811,927.00	1,836,561.00
Gasoline (tonnes)	3.46	2.48	2.34
Total energy consumption ('000kWh)	31,618.62	35,063.56	34,941.31
Direct energy consumption	17,841.02	19,648.35	18,173.96
Indirect energy consumption	13,777.60	15,415.21	16,767.36
Energy consumption intensity per unit of original value of public engineering facilities and machinery equipment ('000kWh/million RMB)	209.11	137.53	117.73
Total Packaging Materials (tonnes)	21.90	15.22	16.65
Inner Packaging Materials	12.27	5.57	9.23
Outer Packaging Materials	9.63	9.65	7.42
Packaging materials per unit of production (g/injection)	57.31	29.61	24.98

Social	2022	2023	2024
Employment			
Headcount	472	435	420
By gender			
Male	198	185	189
Female	274	250	231
By age			
Under 30	168	150	109
30-50	296	276	301
Above 50	8	9	10
By employee category			
Senior management	33	31	31
Middle management	65	66	63
General staff	374	338	326
By employment category			
Employee	472	435	420
Contract employee	0	0	0
By region			
Beijing	41	35	26
Shanghai	41	26	28
Suzhou	338	328	328
Other regions	52	46	38
Employee turnover rate (%)	27	25	26
By gender			
Male	34	23	24
Female	22	26	27

Social	2022	2023	2024
By age			
Under 30	38	39	29
30-50	20	17	25
Above 50	38	11	10
By region			
Beijing	44	34	15
Shanghai	34	77	18
Suzhou	25	17	28
Other regions	21	41	16
Health and Safety			
Number of work-related fatalities (person)	0	0	0
Rate of work-related fatalities (%)	0	0	0
Lost days due to work injury	0	0	0
Development and training			
Percentage of trained employees (%)	100	100	100
By gender			
Male	100	100	100
Female	100	100	100
By employee category			
Senior management	100	100	100
Middle management	100	100	100
General staff	100	100	100
Average training hours completed per employee by gender (hours)			
Male	11	26	35
Female	11	28	40
Average training hours completed per employee by employee category (hours)			
Senior management	11	23	21
Middle management	11	25	33
General staff	11	28	40
Supply chain management			
Total suppliers	1,224	1,325	1,444

Social	2022	2023	2024
By region			
Eastern China	871	946	1,040
Southern China	55	55	59
Central China	54	54	55
Northern China	130	130	135
North-western China	28	25	25
North-eastern China	12	10	10
South-western China	26	25	25
Outside China	48	80	95
Product Responsibility			
Percentage of total products sold or shipped subject to recalls for safety and health reasons (%)	0	0	0
Number of complaints about products and services	4	1	0
Anti-corruption			
Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees	0	0	0
Number of employees enrolled in training by category (person)			
Number of directors enrolled in training	6	5	6
Number of employees enrolled in training	399	435	420
Training duration for each category of employees (hours)			
Anti-corruption training provided to the Company's directors	6	5	6
Anti-corruption training provided to the Company's employees	2,793	1,740	1,260
Community investment			
Cumulative investment in public charity (RMB10,000)	Due to the impact from the COVID-19 pandemic, there was no amount incurred therefrom in 2022	1	1
Total investment in public charity by category			
Education	Due to the impact from the COVID-19 pandemic, there was no amount incurred therefrom in 2022	1	1
Medical devices	Due to the impact from the COVID-19 pandemic, there was no amount incurred therefrom in 2022	0	0
Cumulative time of investment in public charity (hours)	Due to the impact from the COVID-19 pandemic, there was no amount incurred therefrom in 2022	20	8
Total duration of public volunteer service by category (hours)			
Education	Due to the impact from the COVID-19 pandemic, there was no amount incurred therefrom in 2022	20	8
Medical devices	Due to the impact from the COVID-19 pandemic, there was no amount incurred therefrom in 2022	0	0


康宁杰瑞
ALPHAMAB ONCOLOGY